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ABSTRACT 
 
IMMUNOSENESCENCE IN B CELLS: A STUDY ON CHANGES IN IMMUNOREGULATOR 
EXPRESSION AND METABOLISM WITH AGE 
Senthil Kannan 
Dr. Hildegund C.J. Ertl, M.D.  
There is a vital need for better vaccines for the aging population, and especially better vaccines to 
influenza viruses. To address this, I studied immunosenescence in B cells and antibody secreting 
cells (ASCs) in mice and humans. In humans, I measured humoral immune responses to the 
trivalent inactivated influenza vaccine (TIV) during the 2011-12 and 2012-13 influenza seasons. 
ASCs in the aged were observed to have decreased expression of the defining markers CD27 
and CD38. Aged ASCs also expressed lower levels of B and T Lymphocyte attenuator (BTLA) on 
their surface. Expression of BTLA inversely correlated with age and appeared to be linked to 
shifting the nature of the response from IgM to IgG. High BTLA expression on mature B cells was 
linked to higher IgG responses to the H1N1 virus.  Finally, high BTLA expression on isotype 
switched memory B cells was linked to better preservation of virus neutralizing antibody titers and 
improved recall responses to influenza vaccination given the following year. In mice, aged ASCs 
expressed high levels of PD-1 and this correlated with high levels of cellular reactive oxygen 
species (cROS), indicating a link between immunoregulator expression and metabolism. Micro-
array studies of bone marrow-derived ASCs showed substantial differences in their gene 
expression profile in aged as compared to young mice, which may explain their deteriorating 
functions. In summary, expression levels of immunoregulators on ASCs or their precursor 
populations change upon aging. Aged ASCs or their precursors are metabolically different from 
their younger counterparts, and these two factors are linked.  
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CHAPTER 1 - INTRODUCTION 
Aging is an inevitable part of life. In 2014, there were 46.7 million individuals in the U.S, 
who were 65 years of age or older, and they account for nearly 15% of the current 
population of the country (1). As healthcare and medical technologies progress, this 
proportion will continue to increase. The strongest predictor of this is the significant 
increase in life expectancy that we’ve seen over the past century – from only 50 years in 
1900 to 83 in the 21st century (2).   
This increase in life expectancy can be attributed to many technological advances. But 
there are two major breakthroughs that have had a vital role in human longevity – the 
production and availability of clean drinking water and vaccines.  
To merely say vaccines have played a central role in human health would be an 
understatement. They have been singlehandedly responsible for saving millions of lives. 
It is due to vaccines that diseases that were once fatal, like smallpox, have effectively 
been eradicated. Thanks to major scientific breakthroughs, we now have vaccines to a 
wide variety of pathogens – from pediatric killers like rotavirus and measles, to ones like 
influenza and yellow fever, which affect people of all ages.  
Unfortunately, the efficacy of vaccines drops rather sharply with age, as exemplified by 
the trivalent inactivated influenza vaccine (TIV). In the 2012/13 Influenza season, final 
analyses of vaccine efficacy in the US and Canada reported an efficacy of ~ 32% for 
influenza A viruses in the general population. However, in people over 65 years of age, 
the efficacy against influenza A viruses only reached 9%. (3) . This decline in function of 
the immune system with age is called immunosenescence – the major topic of this 
thesis.  
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Immunosenescence affects multiple aspects of both innate (4) and adaptive (5) (6) 
immunity. A carefully orchestrated interaction between the innate and adaptive immune 
systems produces an effective immune response (7) 
In this system, the “first line of defense” towards pathogen invasion is usually the innate 
immune system, which tends to respond consistently to repeated infections, while the 
adaptive immune system prefers a different approach. The adaptive immune system 
responds slower, but in a more specific manner to the initial infection, and upon repeated 
infection it displays immune memory and produces a rapid, specific response against the 
pathogen. This is the immunological basis for vaccines.  
Immunosenescence has been observed to affect multiple facets of the innate immune 
system. Type 1 IFN production by plasmacytoid dendritic cells in response to herpes 
viral infections has been observed to be impaired in the aged. A recent study in mice 
showed that aging affected the upregulation of IRF-7 – a critical transcription factor in 
the type 1 IFN signaling pathway (8). Age-induced oxidative stress was also observed to 
play a role in this phenotype, and thus is of particular interest to this thesis. In humans, a 
recent study from the same investigators reported a reduced ability of plasmacytoid 
dendritic cells from older humans to upregulate IRF-7 in response to a viral infection 
compared to plasmacytoid dendritic cells from younger people (9).  
Another aspect of the innate immune system – NK cells – has also been observed to 
exhibit defects upon aging. This has been well studied in the murine immune response 
to the ectromelia virus – the mouse equivalent of human smallpox. Aged mice exhibited 
increased lethality and defective viral clearance, and most interestingly, did so in a T 
cell-extrinsic manner. Specifically, the accumulation of NK cells at the site of infection (in 
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this case, the footpad) was severely impaired in the aged compared to the young mice 
and this was primarily due to the reduced migration of CD27+CD11b- mature NK cells 
(10).   
The second arm of the immune system is the adaptive immune system. It can be broadly 
divided into cellular immune responses (primarily by CD8+ T cells) and the humoral 
immune responses (by B cells, with/without T cell help). Aging has been shown to affect 
both arms in multiple ways.  
To start with T cells: Alterations within the bone marrow and thymus lead to a shift in the 
composition of the T cell repertoire from naïve to antigen-experienced T cells, thereby 
compromising the diversity of the T cell pool. Additional infections with latent pathogens 
such as cytomegalovirus aggravate this process. A decrease in the number of antigen-
inexperienced naïve T lymphocytes combined with an increase in antigen-experienced 
memory and effector T cells are the most substantial age-related changes within the T 
cell compartment. The initial trigger responsible for the dysregulated balance within the 
composition of the T cell pool observed in elderly persons is the involution of the T cell 
maturation organ, the thymus gland. The functional mass of the thymus decreases with 
age and the consequent reduction in naïve T cell output necessitates the homeostatic 
forces to take more responsibility in ensuring survival of T cells and keeping their 
numbers constant. Another key player in the maintenance of the T cell compartment is 
apoptosis, Apoptosis controls the selection of the T cell repertoire in the thymus, the 
deletion of self-reactive lymphocytes, the regulation of immunological memory, and the 
deletion of effector T cells (11). Further effects of aging on the immune system are 
telomere shortening, changes in T cell signaling, impaired DNA repair, and antioxidant 
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mechanisms, which may all contribute in regulating T cell survival and shaping of the 
repertoire (5).  
The output of peripheral naïve T cells is dramatically reduced in the aged (up to 80%), 
leading to a reduced ability to respond to new antigens. This can happen due to two 
reasons. Firstly, declining Hematopoietic Stem Cell (HSC) functions, due to deficiencies 
in DNA damage and repair, shortening of telomeres and an overall reduction in 
hematopoietic tissue. Secondly, the severe reduction in thymic mass contributes to 
reduced production of mature T cells. The thymus is fully developed at birth, and soon 
after birth it starts getting replaced slowly by fat; by 50 years of age this thymus is almost 
completely composed of fat tissue. In contrast to naïve T cells, memory T cells rely on 
IL-7 in concert with IL-15 to cycle and self-renew in vivo> Memory T cells divide three- to 
fourfold faster than naïve T cells, and are capable of vigorous proliferation under 
lymphopenic conditions. In addition to the decrease in naïve T cell numbers, antigenic 
stimulation by persistent viral infections can challenge the tightly regulated orchestra of 
clonal expansion, contraction, and homeostasis of memory T cell and may thus lead to 
the massive accumulation of clones of certain specificities, culminating in a dramatically 
reduced diversity of the memory T cell pool in elderly individuals (12).  
The other arm of the adaptive immune system – B cells – also exhibits a significant 
decline in function upon aging. Since B cells produce antibodies, the prime correlates of 
vaccine-induced protection against viral infections, they are of particular interest to 
vaccinologists, and thus this thesis. Multiple descriptive studies have shown the effects 
of immunosenescence on various steps in B cell development (13). Commitment to the 
B cell lineage from HSC progenitors involves key transcription networks (14). Once 
committed, the cells enter the pro-B cell stage where recombination activating gene 
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(RAG)-mediated IgH (heavy chain) gene rearrangement occurs. Upon successful IgH 
rearrangement, the cell surface expressed Ig heavy chain is associated with a surrogate 
light chain and the Ig-α and Ig-β signaling complex.  B cells in this stage are called pre-B 
cells. Pre-B cells proliferate briefly, and rearrange their light chains to express a 
complete B cell receptor on their surface. They then transition into their next stage, 
immature B cells (13).  
Immature B cells expressing a complete B cell receptor (BCR) on their surface now 
undergo a stringent specificity based selection, and mature upon exit from the bone 
marrow. This positive selection is vital in B cell development and involves a necessity for 
persistent low level BCR signaling, which results in survival-promoting signals. Thus, 
amongst peripheral B cells, there is a fitness hierarchy based on BCR specificity, with 
primary B cells competing against each other. (13).  
This forms the next pool of B cells – the antigen-experienced B cell subsets –, which 
include memory cells, antibody secreting plasma cells (ASCs) and recently activated B 
cells. B cell responses to a pathogen can be either T cell dependent or independent, 
based on their requirement for cognate T cell help. T cell-independent responses 
generate short-lived IgM-secreting plasma cells, yield little humoral memory and lack 
substantial affinity maturation. On the other hand, T cell-dependent responses produce 
germinal centers, where activated B cells undergo class switch (CSR) and somatic 
hypermutation (SHM), culminating in cells producing the high-affinity class-switched 
antibodies crucial to effective long-term humoral immunity. 
Immunosenescence affects B cells at multiple points along their developmental pathway. 
Upon aging, the frequency of HSC precursors that are capable of generating B cells is 
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reduced, similar to defects seen in T cell development. This results in smaller pools of 
pre-B and immature B cells (15) and thus bone marrow output.  B cell lymphopoiesis is 
reduced with aging, leading to a decline of naïve B cells (16). Primary B cell responses 
in the elderly are commonly low and short-lived, resulting in antibodies with low affinity 
(17). Formation of germinal centers is decreased (18), antigen transport is impaired and 
follicular dendritic cells have reduced capacity to form antigen depots (19). 
Autoantibodies are more common (20) and the B cell repertoire becomes more restricted 
(21). Expression of the E2A-encoded transcription factor E47 is decreased in old splenic 
B cells, which causes a reduction in the activation-induced cytidine deaminase, needed 
for class switch recombination and Ig somatic hypermutation (22). Some of the defects 
of B cell responses are secondary to an age-related decline of helper functions from 
CD4+ T cells, which show reduced expression of critical co-stimulatory receptors (23) 
(24). CD4+ T cells in turn are essential for activation of B cells, germinal center 
formation, rearrangement and hypermutation of immunoglobulin (Ig) genes.  
Since correlates of protection for most vaccines are neutralizing antibodies, the question 
how antibody secreting cell (ASCs), which are responsible for the production of 
neutralizing antibodies, change with age needs to be addressed. This led to the main 
hypotheses of this thesis:   
a. Expression levels of immunoregulators on ASCs or their precursors change upon 
aging.  
b. Aged ASCs or their precursors are metabolically different from their younger 
counterparts  
c. These two factors are linked.  
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To address these hypotheses, I carried out a number of studies with human samples 
and in mice. In humans, I adopted an antigen-specific approach, using TIV, and studied 
immune responses to this vaccine. In mouse studies, due to the increased experimental 
freedom and availability of more complex sources of cells and tissues, such as spleen 
and bone marrow isolates, I was able to ask questions that could not be addressed with 
the more limited samples from human studies. This included a detailed look into age-
related differences in gene expression profiles, metabolic changes upon aging, and their 
relation to immunoregulator expression.  
Why did I choose to study influenza? Influenza is one of the top 10 causes of death in 
older adults. TIV consisting of two strains of influenza A and one or two strains of 
influenza B virus is approved for use in the elderly, but affords incomplete protection (25) 
(26). This incomplete protection to TIV has been linked in part to poor stimulation of B 
cells producing virus-neutralizing antibodies.  
 
I started this study in 2011, to assess B cell responses of the aged to TIV in the post 
2009 pandemic phase.  I tested these responses in aged individuals of or above 65 
years of age to the influenza A virus components of the 2011/12 TIV in comparison to a 
cohort of middle-aged individuals of 30-40 years of age.  
The primary objective of the study was to compare antibody and B cell responses of the 
two cohorts with regard to magnitude and kinetics of responses using three 
complementary assay systems.  
As expected, most individuals of the middle-aged cohort responded to both influenza A 
virus strains. Aged individuals more commonly responded to the H1N1 virus than to the 
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H3N2 virus. Interestingly within responders, vaccine-induced neutralizing antibody titers 
to H3N2 were comparable in magnitude between aged and younger individuals while the 
aged cohort mounted significantly lower neutralizing antibody titers to the H1N1 virus. At 
baseline, the aged had significantly higher levels of circulating IgG to both viruses 
compared to younger individuals. Analyses of peripheral blood mononuclear cells 
(PBMCs) by ELISpot assays showed no difference in responses between younger and 
aged individuals suggesting that low antibody responses in the aged related to cell 
intrinsic defects rather than lack of responding cells. Analysis of CD19+ PBMCs by 
staining for CD27 and CD38 to detect ASCs by flow cytometry, a method, which upon 
influenza virus vaccination primarily detects vaccine-induced cells, showed only marginal 
increases in circulating ASCs in the aged while younger individuals showed far more 
pronounced increases. There was a pronounced discrepancy in the aged between 
results obtained by flow cytometry and ELISpot assays in that the former appeared to 
underestimate the vaccine-induced increases in ASCs observed with the latter. Further 
analysis suggested that in the aged, ASCs express reduced levels of CD27 and CD38. 
This is an important finding as loss or reduced expression of these two molecules, which 
are both involved in crucial signaling pathways, may negatively affect ASC functions. It 
also made the flow cytometric analysis of ASC frequencies in the aged unreliable as it is 
based on the detection of these two markers.  A secondary objective of this study was to 
optimize time points post vaccination for optimal ASC retrieval, the completion of which 
directly led me to pursue my next human study.  
In the second study conducted during the 2012-13 influenza season, I focused on 
expression of immunoregulators on different B cell populations, i.e., transitional B cells, 
mature naïve B cells, unswitched and switched memory B cells, double-negative B cells, 
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and antibody secreting cells (ASCs) defined by stains for CD19, IgD, CD20, CD27, and 
CD38 from aged and younger individuals before and on days 7 and 14 after TIV. In 
addition, I analyzed the VNA response to the two influenza A virus strains of TIV, i.e., 
H1N1 A/California/7/2009 pdm09-like virus and H3N2 A/Victoria/361/2011 virus to 
assess if the expression of immune regulators was linked to responsiveness to 
vaccination. 
My results show that, as observed in the study of the previous year, the younger 
individuals mounted higher VNA responses to both viruses and had higher numbers of 
naive B cells compared to the aged. The B and T lymphocyte attenuator (BTLA), which 
upon interactions with the herpes virus entry mediator (HVEM) provides inhibitory 
signals (27) was significantly higher expressed on B cells from younger compared to 
aged individuals at baseline. BTLA, as well as percentages of BTLAhi B cells, selectively 
increased in the aged after vaccination so that differences between the two cohorts 
cease to be significant. Individuals with high BTLA on their mature B cells had better IgG 
responses to the H1N1 virus, compared to those with low BTLA. Further analysis 
showed that individuals with high BTLA expression levels showed better preservation of 
H1N1- and H3N2-specific VNA titers and superior booster response to the next annual 
dose of TIV compared to those with BTLAlo switched memory B cells. Overall these 
results show that a decline of BTLA during immunosenescence might contribute to lack 
of sustained antibody responses in the aged and to a reduction in their ability to mount 
recall responses. 
Another hypothesis that I addressed was that immunosenescence causes metabolic 
changes in aging B cells and ASCs, which may in part be linked to differential 
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expression of immunoregulators. Immunosenescence involves a gradual deterioration of 
many biological processes. For example, the genome becomes unstable and 
accumulates mutations due to exogenous insults as well as endogenous sources of 
DNA damage such as increased production of reactive oxygen species (ROS), 
replication errors and declines in DNA repair mechanisms (28) (29). Mitochondrial DNA 
also becomes increasingly damaged in a similar fashion and energy production through 
the respiratory chain deteriorates (30).  
Hence, in the third chapter, I further elucidated age-related defects in B cell metabolism 
using mice. In addition I tested if changes in metabolism are linked to changes in co-
inhibitor expression. Whole genome expression arrays comparing bone marrow-derived 
ASCs from young and aged mice showed disparity of expression in over 1500 genes 
and distinct clustering. Genes that were differentially expressed participate in numerous 
pathways and functions including immunological and metabolic functions. Aged B cells 
have increased levels of ROS and show differential expression of immunoregulators 
such as PD-1. Expression of PD-1, which is known to affect key metabolic pathways, is 
strongly correlated with levels of cellular (c) ROS. Defects in mitochondrial functions 
were further confirmed upon in vitro stimulation of B cells.  
In summary, this thesis addresses immunosenescence in B cells, specifically ASCs and 
their precursors from two perspectives – changes in expression of immunoregulators, 
their metabolism, and the relationship between these two factors.  
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CHAPTER 2 – B CELL RESPONSES TO THE 2011-12 INFLUENZA VACCINE IN THE 
AGED  
Abstract:  
Antibody and B cell responses to influenza A viruses were measured over a period of 2 
months in 30 aged and 15 middle-aged individuals following vaccination with the 
2011/12 trivalent inactivated influenza vaccine by micro-neutralization assays, ELISAs, 
ELISpot assays and cell surface staining with lineage-defining antibodies followed by 
multicolor flow cytometry. Both cohorts developed comparable antibody responses to the 
H3N2 virus of the vaccine while responses to the H1N1 virus were compromised in the 
aged. ELISpot assays of peripheral blood mononuclear cells (PBMCs) gave comparable 
results for the two cohorts. Analysis by flow cytometry upon staining of CD19+IgD-CD20- 
PBMCs with antibodies to CD27 and CD38 showed markedly reduced increases of such 
cells following vaccination in the aged. Additional analysis of cells from a subset of 10 
younger and 10 aged individuals indicated that in the aged a portion of IgG producing 
cells fail to express CD27 and have reduced expression of CD38. 
Introduction/purpose of study:   
The aim of this study was twofold. Firstly, I wanted to study the kinetics of the humoral 
immune response to the TIV. Specifically, how different are the kinetics between the two 
aged groups. Would the aged respond poorer and slower? Secondly, I needed to 
optimize time points post vaccination for optimal ASC retrieval in subsequent studies.  
Study design:  
To assess responses of the aged to TIV in the post 2009 pandemic phase, we tested B 
cell responses of 30 aged individuals of or above 65 years of age to the influenza A virus 
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components of the 2011/12 TIV in comparison to a cohort of 15 middle-aged individuals 
of 30-40 years of age. As stated earlier, the objective of the study was to compare 
antibody and B cell responses of the two cohorts with regard to magnitude and kinetics 
of responses using three complementary assay systems. Details of our enrollment 
criteria are specified in the materials and methods section of this chapter. Basically, we 
only included immunocompetent individuals who did not have any chronic or other 
illnesses that would prevent completion of the study such as respiratory infections, and 
those with a history of substance abuse, and allergies to the components used in the 
TIV.  
The subjects were vaccinated with the TIV by our collaborators at Duke University, and 
blood was collected from them before vaccination and at five time-points post 
vaccination – days 7, 10, 14, 28 and 60.  
Results:  
Human subjects:  
Twenty subjects reported influenza vaccination during the previous 5 years, 3 were 
unsure and 2 reported influenza-like illnesses. Thirteen of those that reported previous 
vaccinations had been immunized in 2010 when the pandemic H1N1 strain was 
incorporated into the vaccine. Sixteen individuals between 30-40 years of age with an 
average age of 36 were enrolled and 15 completed the study. 9 of the 15 younger 
individuals were female and 6 were male, 9 were Caucasian, 5 were African American 
and 1 was of mixed ethnicity. The average age of the aged cohort was 74 ranging from 
65-87. 20 individuals were female, 10 were male. The majority [20] was Caucasian, two 
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were African Americans, one was of mixed ethnicity and one was either American Indian 
or Alaskan Native.  
There were no serious adverse events (SAEs) following vaccination in either age group. 
Neutralizing antibody responses to the vaccine are comparable:   
Serum was isolated from the blood collected at the previously mentioned time points, 
and tested for vaccine-specific antibodies by two methods. Microneutralization assays 
were performed to measure levels of neutralizing antibodies and Enzyme Linked 
Immuno-Sorbent Assays (ELISAs) were performed to measure levels of virus-binding 
antibodies. Both assays were conducted in a virus-specific manner against the two A 
strains of the influenza virus in the 2011-12 TIV (H1N1 A/California/04/2009 and H3N2 
A/Perth/16/2009).   
At baseline, both cohorts had comparable antibody titers to the two viruses. Percentages 
of individuals with antibody titers of or above 1:40 to either virus were slightly higher in 
the aged than in the younger cohort with 33% of younger vs. 40% of aged being positive 
for H1N1 virus (p=0.725) and 40% of younger vs. 60% of older individuals being positive 
for H3N2 virus (p=0.466). Aged subjects, who were enrolled towards the end of the 
study, more commonly had neutralizing antibody titers of or above 1:40 than those that 
were enrolled earlier. More specifically of the 11 elderly individuals that were first tested 
after Mid-March of 2012, 91% were sero-positive for the H1N1 virus while 72% were 
positive for the H3N2 virus. In contrast of the 19 aged individuals recruited early only two 
(i.e., 11%) was positive for antibodies to H1N1 at the time of vaccination (p<0.001) while 
10 (52%) were sero-positive for the H3N2 virus (p=0.490). This bias at baseline was not 
seen for younger individuals all of whom had been enrolled by the end of February. 
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Upon vaccination 8 aged individuals failed to respond to the H1N1 virus and 10 were 
unresponsive to the H3N2 virus.  
Importantly, kinetics of antibody responses differed between the two cohorts, albeit 
slightly. (Figure 1) Average titers peaked in the younger cohort by day 10 after 
vaccination and only marginally declined by the end of the study. In the aged peak titers 
to H1N1 were also reached by day 10 after vaccination while average peak responses to 
the H3N2 virus were delayed to day 14 reflecting a significant difference in time to peak 
response (p = 0.0316). The decline of antibody titers was more pronounced in the aged 
although this did not reach significance (p = 0.057).   
To summarize, neutralizing antibody responses were comparable between the two age 
groups, but a potential shift in kinetics was observed.  
 
Figure 1: Antibody Titers. Titers of H1N1-specific antibodies in individual sera are 
shown for aged and younger subjects in the first column. Titers of H3N2-specific 
antibodies in individual sera are shown in the second column. Mean titers of H1N1 
(closed circles) and H3N2 (open circles) are shown in the column on the right. * 
indicates significant differences from baseline/ day 0.  
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Binding antibody responses to the TIV are comparable, but the kinetics of the 
response are different:  
To test for antibody isotypes, sera collected at baseline and on days 10 and 28 following 
vaccination were tested by ELISAs on plates coated with H3N2 or H1N1 virus (Figure 
2).  
 
Figure 2. Antibody Isotypes. Serum samples collected on days 0, 10 and 28 following 
vaccination were tested for IgA, IgG and IgM to H1N1 and H3N2 viruses by ELISAs. 
Graphs show average titers ± SEM. * indicates statistical significance (p<0.05) as 
calculated using the Mann Whitney test. + indicates statistical significance (p<0.05) as 
difference between age groups as calculated using the Mann Whitney test. 
 
At baseline, antibody responses were slightly higher in the aged although this only 
reached significance for H3N2-specific IgA. The younger cohort responded quicker, 
* * * *
*
*
*
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+
* *
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showing significant increases by day 10, in all three isotypes (IgA, IgG and IgM) to both 
viruses. The aged, on the other hand, mainly showed significant increases in binding 
antibody titers by day 28. The only exception was the IgM response to H1N1, which 
increased by day 10.  
Responsiveness by ELISA differed between the two cohorts. Responsiveness is defined 
as a 4 or more fold increase in circulating antibodies of either isotype at either of the two 
time points. One of the younger individuals failed to show responsiveness to H3N2 virus, 
while three failed to respond to H1N1; the non-responder to H3N2 virus also failed to 
respond to H1N1 virus. Non-responsiveness by ELISA was more common in the aged; 3 
and 11 individuals failed to show significant increases of antibodies of either isotype to 
H3N2 and H1N1 virus, respectively on either day 7 or 28. Of the non-responders, the 3 
individuals that failed to respond to H3N2 virus also did not develop increased antibodies 
to H1N1 virus. Aged individuals, who did not mount a recall response to H1N1 virus, had 
significantly higher levels of specific IgG at baseline (p<0.05) compared to responders. 
The same trend was seen for H3N2 virus but failed to reach significance. 
In summary, binding antibody responses to the TIV were comparable between the two 
age groups, but the kinetics were considerably different, with the younger cohort 
responding quicker to both the H1N1 and H3N2 viruses.  
Circulating B cell populations are lower in the aged:  
The two B cell subsets that serve as precursors to my population of interest (ASCs) are 
naïve mature B cells and memory B cells. So, I measured these two subsets. Aged 
individuals had significantly lower number of naïve B cells at baseline (p = 0.004) and 
numbers remained stable after vaccination (Figure 3).  
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Figure 3. Circulating B cells. 3A shows numbers of naïve B cells per 106 CD3-CD14-
 live PBMCs. Naïve B cells (NBCs) were identified by gating on 
CD19+CD20+CD27+CD38-IgD+ cells. (a) shows data for PBMCs from individual aged 
subjects, (b) shows means of the same set of data, (c) shows data for PBMCs from 
individual younger subjects, (d) shows means for the same data. 3B shows numbers of 
memory B cells per 106 CD3-CD14- live PBMCs. Memory B cells were identified by 
gating on CD19+CD20+CD27+CD38-IgD- cells.  
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In younger individuals, numbers significantly (p=0.045) declined by day 10 following 
vaccination and for the duration of the study remained below levels seen at baseline. 
Memory B cells were also higher in younger than aged individuals (p = 0.002) at 
baseline and in the both cohorts significantly declined by day 10 following vaccinations 
(p = 0.016 for the younger and 0.036 for the aged).    
Vaccine-induced circulating influenza virus-specific ASCs are comparable:  
PBMCs from 10 younger and 28 aged individuals collected at the 6 time points 
mentioned were analyzed for vaccine-induced responses to the two influenza A viruses 
of the vaccine by ELISpot assays (Figure 4). Responders based on this assay had to 
show at least a 2-fold increase in ASCs and a minimum of 10 influenza virus-specific 
spots per 106 PBMCs following vaccination.  
   
Figure 4. ELISpot Results. Spots per 106 live PBMCs are shown for individual samples 
in the first two columns. Mean results for aged and younger subjects are shown in the 
column on the right. The graphs are arranged as in Figure 1. 
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At baseline only two versus four aged individuals had ≥10 spots to H1N1 or H3N2 virus, 
respectively. Three aged individuals failed to respond to the H1N1 vaccine; seven aged 
subjects did not show an increase in H3N2-specific spots. Of the 10 younger individuals, 
3 had positive spots for H1N1 virus while 6 were positive for H3N2 virus at baseline. Two 
younger subjects failed to respond to H1N1 virus; five younger individuals failed to 
respond to H3N2 virus. The kinetics of responses in the aged showed a sharp peak on 
day 7 to both viruses, which was followed in some individuals by additional smaller 
peaks on days 14 or 28. Younger individuals showed peaks either on days 7 or 10. 
There was no significant difference in magnitude or time to peak responses between the 
two cohorts. In summary, virus-specific ASCs were comparable between the two cohorts 
when measured by ELISpot assays.  
Circulating ASCs measured by flow cytometry are significantly lower in the aged:  
ASCs can be identified by cell surface markers that distinguish different B cell 
populations. Specifically, in humans ASCs are negative for IgD and CD20 but express 
high to intermediate levels of CD19 and high levels of CD38 and CD27. Upon influenza 
vaccination a transient rise in circulating ASCs is mainly reflective of vaccine-induced 
cells and up to 80% of such cells secrete antibodies specific to the antigens in the 
vaccine. PBMCs were therefore stained with lineage-defining antibodies before and at 
the indicated time points after vaccination. Samples were analyzed by flow cytometry 
and the post-acquisition-gating scheme is shown in Figure 5, data are shown in Figure 
6. 
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Figure 5. Gating scheme for ASCs. Graphs on the bottom right shows results of a 
young individual at baseline and 7 days post-vaccination  
 
 
Figure 6. Circulating ASCs. Graphs show numbers of circulating ASCs per 106 CD3-
CD14- live PBMCs.  
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Individuals with more than 1000 circulating ASCs over 106 CD3-CD14-live lymphocytes 
were defined as high baseline responders; subjects that showed an at least 2-fold 
increase in ASCs over baseline within 14 days following vaccination were deemed 
responders.  
The younger cohort developed significantly higher numbers of ASCs upon vaccination 
than the aged (p = 0.013) despite having a significantly higher portion of subjects with 
high ASC counts at baseline (7/15 vs 4/30 in the aged; p = 0.04 by Fischer exact t-test) 
Four younger subjects failed to show increases in ASCs within 2 weeks after 
vaccination, two of those had high ASC counts at baseline. Sixteen of the aged 
individuals failed to show a two-fold increase in ASCs and this included all of the 
subjects with high ASC numbers at baseline. Again correlation with antibody 
responsiveness to vaccination was poor, only one of the subjects that failed to show 
increases in ASC numbers failed to show an antibody response to the H3N2 virus of the 
vaccine. 
Several human subjects reported symptoms indicative of an infection during the 60-day 
follow-up period of the study. Specifically 8 aged individuals reported coughs, runny 
noses or sinusitis at the 5th or 6th study visit by when vaccine-induced changes in ASC 
counts should have subsided. Of those 5 showed delayed increases in ASC counts, 
which coincided with their cold symptoms. Of the 6 younger individuals, who reported 
cold-symptoms at either of the last two visits, none developed accompanying increases 
in ASC counts. 
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Expression of CD27 and CD38 is decreased on aged ASCs:  
Poor responses in the aged as measured by increases in circulating ASCs detected by 
high expression of CD38 and CD27 on CD20-IgD-CD19+ cells following vaccinations did 
not correspond to the results obtained by ELISpot assays, which revealed comparable 
influenza virus-specific ASC frequencies in blood of younger and aged individuals by day 
7 following vaccination. This may have reflected that key markers, which were used for 
identification of ASCs by flow cytometry, were differentially expressed depending on 
age. We therefore repeated the cell stains with day 7 cryopreserved PBMC samples 
from 10 younger and 10 aged individuals including an intracellular stain for IgG, which is 
only present in isotype-switched ASCs. After flow cytometry, blots were gated on ASCs 
based on high expression of CD38 and CD27 as shown in Figure 4. Alternatively they 
were gated onto CD3-CD14-CD20-IgD-CD19+IgG+CD38+ cells relaxing the CD38 gate 
and including cells that showed intermediate expression (Figure 7). In either cohort, 
cells that showed high expression of CD38 also carried high levels of IgG. A second 
population that was mainly detected in the aged expressed intermediate levels of CD38 
and carried intermediate levels of IgG. Cells of this subset were largely CD27-. Of note 
CD20+ cells were IgG-, indicating that IgG+ cells that were detected by the analysis did 
not belong to the memory B cell pool, which express CD20 and surface IgG.  
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Figure 7: Expression of intracellular IgG: Graphs on top left show day 7 ASCs the 
graphs on the left show PBMCs of representative aged/younger individuals harvested 7 
days after TIV vaccination. Cells were gated onto live CD3-CD14-IgD-CD20-CD19+ 
cells. They were then gated onto CD38 over IgG. The smaller gate shows CD38hiIgGhi 
cells, the larger gate shows cells that are CD38int-hi and IgGint-hi.  Graph on top right 
shows the ratios of normalized cells obtained with the CD38int-hi IgGint-hi gate or the 
traditional ASC gate as shown in Figure 5. Means and SDs are shown. Graphs on 
bottom show another representative younger/aged individual as described in the top 
half, with histograms showing CD27 expression on the right.  
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Calculating numbers of ASCs based on either gating scheme, and then comparing the 
results showed that in younger individuals, both gating schemes resulted in 
approximately equal numbers of ASCs indicating that cells positive for intracellular IgG 
were also high in CD38 and CD27. In the aged, the latter gating scheme in most 
individuals resulted in markedly higher numbers of cells (p = 0.001) (Figure 7) indicating 
that portion of the IgG-producing cells in the aged had reduced expression of CD38 and 
lacked expression of CD27 (shown in the second part of the figure with CD27 
histograms). 
Discussion:  
Here, I tested acute B cell responses following TIV vaccination given in winter and spring 
of 2011/12 to cohorts of aged and middle-aged human subjects residing in the Triangle 
area of North Carolina. The study was undertaken to compare antibody and B cell 
responses of the two cohorts with regard to magnitude and kinetics of responses using 
three complementary assay systems. 
A higher percentage of the aged cohort (63%) compared to the younger cohort (27%) 
reported influenza vaccinations during the 5 years prior to the study. However, average 
neutralizing antibody titers and percentages of individuals with neutralizing antibody titer 
≥1:40 at baseline to either of the two strains of influenza A viruses present in the vaccine 
were comparable between the two groups. In contrast, binding antibodies of the IgG 
isotype to H1N1 and H3N2 were significantly higher prior to vaccination in the aged. This 
discrepancy may reflect that IgG antibodies in the aged at baseline were primarily 
directed to conserved non neutralizing epitopes that were shared between the vaccine 
strains and other previously circulating strains. Aged subjects that reported vaccinations 
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or infections during the 5 years prior to this study had on average higher neutralizing and 
binding antibody titers at baseline as compared to individuals that had not been exposed 
to antigens of influenza virus. This difference reached significance for H3N2-specific 
neutralizing antibodies (p = 0.035) and for binding IgG to both viruses. Aged subjects 
that were first vaccinated after mid-March of 2012 showed increased rates of 
neutralizing antibodies to the two influenza A virus strains prior to vaccination and 
differences in titers were significant for both viruses. In most years influenza activity is 
highest in January or early February and then declines. In the 2011/12-influenza season, 
positive tests reported to the CDC did not peak till mid-March. It is thus tempting to 
speculate that an increased portion of aged subjects that were not vaccinated till mid-
March had experienced subclinical infections, which had elicited B cell recall responses. 
Upon vaccination most subjects of the younger age group showed increases in 
neutralizing antibody responses that were comparable between the two influenza A virus 
strains at all time points tested. Lack of neutralizing antibody responses was more 
common to the H3N2 virus. 2 out of the 3 younger non-responders to H3N2 were 
noteworthy since they lacked specific antibodies at baseline in contrast to the one 
younger non-responder to H1N1 who had robust baseline titers. The aged cohort also 
had a higher proportion of individuals who failed to show increases in neutralizing 
antibodies to both viruses - H1N1 (27% of aged vs. 7% of younger) or the H3N2 (33% 
vs. 20%). After vaccination, neutralizing antibody responses to H3N2 virus of aged 
individuals were comparable in magnitude to those of younger individuals. Peak 
antibody responses to H3N2 virus were seen at day 14 in the aged and were slightly 
delayed compared to the younger cohort, which reached maximal responses by day 10. 
Antibody responses to H1N1 virus were compromised in the aged. Average titers upon 
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vaccination, comparing titers either in all individuals or only in responding individuals 
were both significantly below those in younger individuals (p = 0.037 for all individuals, p 
= 0.011 excluding non responders) at all time points tested. These results are in contrast 
to a previous study, which reported increased antibody responses in the post pandemic 
phase to H1N1 vaccination (31) but in agreement with a study conducted in Singapore 
which also reported decreased responses to the H1N1 vaccine in aged individuals (32) 
and another study conducted prior to the 2009 pandemic, which showed good 
responses to H3N2 and poor responses to H1N1 in the aged (33). 
 In this study, aged subjects that reported neither influenza vaccinations nor infections 
during the 5 years prior to this study developed significantly lower titers to H1N1 upon 
vaccination (p = 0.011) as compared to those who recalled either. Yet again, this is in 
contrast to a previous study, which showed that in adults between 22-49 years of age 
recent vaccination decreased antibody responses to vaccination with TIV (34) and may 
indicate that the aged are able to mount recall responses but have defective primary 
responses to TIV. Previous studies have reported that vaccine-induced antibody 
responses decline more rapidly in the aged (35). In our study, although average titers in 
the aged declined more markedly by two months after vaccination than in younger 
individuals this difference was subtle and did not reach significance (p = 0.057). 
Initially at day 7 after vaccination both cohorts showed significant increases in IgM to 
H3N2 and H1N1 suggestive of primary responses. Both cohorts also mounted significant 
IgG responses to both viruses, which are likely to reflect recall responses. Interestingly, 
the pattern of the IgG and to some degree the IgM responses differed between the 
younger and aged cohorts; IgG and IgM responses to H1N1 and IgG responses to H3N2 
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were higher on day 7 than day 28 in younger individuals while in the aged IgG and IgM 
titers to both viruses increased between days 7 and 28. The pandemic H1N1 virus was 
routinely incorporated into the annual vaccine as of 2010. Thirteen of the aged individual 
received the influenza vaccine in 2010. These individuals had significantly higher levels 
of H1N1-specific IgG at baseline (p = 0.001). Upon vaccination their IgG responses to 
H1N1 were initially higher on day 7 than those of aged individuals that had not been 
vaccinated in 2010 but by day 28 after vaccination responses including isotypes of 
H1N1-specific antibodies were indistinguishable between the two aged subgroups. 
Neutralizing antibody titers became significantly higher in 2010 vaccine recipients on 
days 10 and 14 following vaccination in 2011. Again, this difference was not sustained. 
Patterns of responsiveness assessed by the ELISpot assay, which detects all antibodies 
to influenza virus regardless of their function, differed from those of circulating 
antibodies. Younger individuals more commonly had positive responses at baseline and 
were less likely to respond with 20% and 50% showing no responses to H1N1 and H3N2 
virus respectively. Non-responsiveness in the younger cohort was with one exception 
only observed in subjects that had either ≥ 10 spots per 106 PBMCs at baseline or had 
neutralizing antibody titers ≥1:40 at baseline; the one exception reported annual 
influenza vaccinations. Within the aged cohort only 11% failed to show increases of 
circulating B cells to H1N1 virus while 24% lacked responses to H3N2 virus. Lack of 
responsiveness by ELISpot in the aged was only seen in individuals with high numbers 
of specific spots at baseline or recent vaccinations. 
In the younger cohort, peak ELISpot responses to both viruses were observed between 
days 7-14 with subjects that had high spot numbers at baseline typically responding 
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later. The aged showed a dominant peak on day 7 followed in some individuals by a less 
pronounced increase on day 14. Two aged individuals showed delayed peaks on day 28 
following vaccination, and both reported previous vaccinations and had high antibody 
titers at baseline. Magnitude of responses to either virus was not significantly different 
between the two cohorts. 
The most pronounced age-related defects were seen upon staining of CD19+ PBMCs 
with antibodies to CD27 and CD38, which are typically used to identify ASCs. Upon 
exposure to antigen, naïve and memory B cells are stimulated and after undergoing 
antigen-driven proliferation and/or hypermutations can transiently be detected in blood. It 
has been reported that, in young individuals by day 7 following influenza vaccination, up 
to 80% of circulating ASCs are specific to antigens of the vaccine (36). Younger 
individuals had significantly higher baseline numbers of circulating ASCs as compared to 
the aged, as has been reported previously (37). Upon vaccination 73% of the younger 
individuals showed marked increases in CD38hiCD27hi ASCs by day 7, which then 
decreased by day 10 and again in 73% of individuals increased by day 14. Lack of 
increases on day 14 were seen in younger individuals that reported recent vaccination 
suggesting that the ASCs circulating on day 7 were primarily derived from memory B 
cells while those on day 14 reflected de novo stimulated B cells. Of the aged, only 37% 
vs. 30% showed increases in CD38hiCD27hi ASCs by day 7 and 14 respectively. 
Contradicting results obtained by two of the antigen-specific methods of antibody and B 
cell detection, i.e., the microneutralization and the ELISpot assays, with the former unlike 
the latter showing reduced responsiveness mainly to the H1N1 virus in the aged can 
easily be explained; the microneutralization assay only detects antibodies to neutralizing 
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epitopes of the viral surface antigens while the ELISpot measures circulating ASCs to 
influenza virus regardless of their fine-specificity or function and thus allows for detection 
of B cells producing antibodies to non-neutralizing and more conserved epitopes. 
Furthermore, influenza virus-specific ASCs of the aged may have produced on average 
lower numbers of antibody molecules, which would have resulted in reduced neutralizing 
antibody titers without affecting numbers of specific ASCs. We view this as unlikely as 
increases of H1N1-specific antibodies following TIV measured by ELISA were similar in 
aged and younger individuals, suggesting that aged B cells more commonly produced 
non neutralizing antibodies directed presumably to epitopes that are conserved between 
the 2011 H1N1 vaccine strain and previously circulating strains, a principle long known 
as "antigenic sin" (38). Such cross-reactive antibodies may be less suited to provide 
protection against infection. Contradicting results obtained by surface staining and 
ELISpot assays, with the former indicating defective responses in the aged while the 
latter showed comparable responses in both cohorts, are harder to reconcile. We, like 
others, identified ASCs by expression of CD19, a pan B cell lineage marker, and high 
expression of CD27 and CD38 on CD3-CD14-IgD-CD20- cells. It is feasible that upon 
aging expression of these markers declines on ASCs. It is well known that in the elderly 
expression of the co-stimulator CD28 declines on T cells resulting in reduced T cell 
responsiveness (39). CD27 is a member of the tumor necrosis family and signals 
through the tumor necrosis factor receptor-associated factors (TRAF) 2 and 5 to activate 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) and mitogen-
activated protein kinase (MAPK) 8 and JUN (40). On B cells it is a marker of previous 
encounter with antigen and thus used to define memory B cells. CD27- memory B cells 
have been described and it is thought that such B cells are either induced outside 
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germinal centers (41) or prematurely leave germinal centers before they acquire CD27 
(42). CD27- memory B cells show lower frequencies of somatic hyper-mutations 
compared to their CD27+ counterparts (43) suggesting either the lack of or incomplete 
maturation within germinal centers. In the aged, numbers of circulating IgD-CD27-
 memory B cells increase (44), which presumably reflects defects in germinal center 
formation and our results suggest lack of CD27 on recently activated circulating ASCs. 
CD38, which distinguishes ASCs from memory B cells, is also expressed on activated T 
cells and previous studies have shown a decline of CD8+CD38+ T cells during aging (45). 
Cell surface expressed CD38 upon its ligation activates the phosphoinositide 3-kinase 
(PI3K) pathway, which through Protein Kinase B (Akt) and the mammalian target of 
rapamycin (mTOR) increases glucose uptake and glycolysis thus meeting the increased 
energetic needs of activated lymphocytes. Intracellular CD38, which was not assessed 
by our staining method, also cannibalizes nicotinamide adenine dinucleotide (NAD) (46) 
and thereby reduces the activity of sirtuin-1, a nuclear energy sensor which increases 
stress-resistance and influences metabolism through promotion of gluconeogenesis, 
fatty acid oxidation, and mitochondrial biogenesis (47) (48). Reduced surface expression 
of CD38 by aged ASCs would thus be expected to negatively affect cell metabolism, 
which is compatible with our finding of markedly lower levels of IgG in CD38int as 
compared to CD38hi cells.  
In summary, in the 2011/12 influenza season aged individuals responded well to the 
H3N2 virus of TIV but mounted lower responses to the H1N1 virus. ASCs of the aged 
showed reduced expression of two signaling molecules which corresponded with 
reduced levels of IgG production, revealing a novel and hitherto undescribed defect of 
adaptive immunity that arises during immunosenescence. 
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The goal of this study was to compare the responses to the TIV in the aged cohort to the 
young, and also establish post-vaccination time points for future studies. I successfully 
achieved both goals, and identified days 7 and 14 post vaccination for optimal ASC 
retrieval. This helped me focus on the next study – measuring immunoregulator 
expression levels in aged B cells – the next chapter in this thesis.  
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Materials and methods: 
Viruses: Stocks of H1N1 A/California/04/2009 and H3N2 A/Perth/16/2009, the two 
influenza A virus strains of the 2011 influenza vaccines, were obtained from the Center 
for Disease Control, Atlanta, Georgia. Viruses were expanded in 10 day-old specific 
pathogen-free (SPF) embryonated eggs for 48hrs at 35°C. After 48hrs allantoic fluid 
from the infected eggs was isolated and concentrated by centrifuging at 20,000rpm for 1 
hour at 4°C. The pellet was re-suspended in PBS and further purified by a 55-10% 
sucrose density gradient. The virus was titrated by hemagglutination assay with chicken 
red blood cells. The mean tissue culture infective dose (TCID50) was determined by 
serially diluting virus on Madin-Darby Canine Kidney (MDCK) cells and screening cells 3 
days later for viral plaques. Infectious virus was used for neutralizing antibody assays or 
inactivated by a 45-minute treatment with betapropionolactone for ELISpot assays. 
Human Subjects: Blood was collected after informed consent from community dwelling 
persons in the Durham-Raleigh-Chapel Hill area of North Carolina. Younger individuals 
were 30-40 years of age; older individuals were ≥ 65 years of age. The following 
subjects were excluded from the study: [1] humans with immunosuppression resulting 
from diseases (e.g., clinically active malignancy, HIV/AIDS, immune disorders) or drugs 
(e.g., cancer chemotherapy, corticosteroid use); [2] individuals with significant underlying 
diseases that would be expected to prevent completion of the study; [3] subjects, which 
were bed-ridden or homebound or had intercurrent illnesses that might interfere with 
interpretation of study (e.g., urinary tract infection, respiratory tract infection); [4] 
individuals that were unlikely to adhere to protocol follow-up; [5] subjects that were 
involved in a conflicting study; [6] subjects that had a history of alcohol or substance 
abuse; [7] subjects with contraindication for influenza vaccination such as anaphylactic 
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hypersensitivity to eggs or to other components of the influenza vaccine, and moderate 
or severe acute illness with or without fever, and Guillain-Barre Syndrome within 6 
weeks following a previous dose of influenza vaccine. Persons with moderate to severe 
acute febrile illness were not vaccinated until their symptoms have abated. 
From enrolled subjects demographic data and medical history including medical 
diagnoses, medications, vaccination to influenza and other infectious diseases, and 
history of influenza or influenza-like diseases during the last 5 years were recorded. 
Subjects were bled and then vaccinated with TIV via the intramuscular route in the 
deltoid muscle. Subjects were bled again on days 7, 10, 14, 28 and 60 following TIV 
vaccination. Change in medical history, change in medications, influenza-like illness, 
adverse events (AE) and SAEs were assessed by solicited reports at each study visit 
and unsolicited reports from subjects at any time after study enrollment. Solicited AEs 
included symptoms of influenza-like illness and injection site complaints, including pain, 
tenderness, redness, and swelling. 
Collection of Blood and Isolation of PBMCs and Plasma: Blood was collected into 
heparinized tubes and shipped overnight to Philadelphia. A 2 ml aliquot of each sample 
was set aside for serum collection. PBMCs were isolated from the remaining samples 
using established protocols. Specifically, blood was overlaid onto Ficoll-Paque Plus (GE 
Healthcare Biosciences, Piscataway Township, NJ) and spun for 30 minutes at 2000 
rpm, with brake off, and at 50% acceleration. The PBMC layer at the Ficoll interface was 
then collected and washed twice with Hank's Balanced Salt Solution (Gibco, Grand 
Island, NY), by centrifuging at 2000 rpm. The washed, pelleted cells were then treated 
with 10 ml of red blood cell lysis buffer (eBioscience, San Diego, CA). Lysis was stopped 
by adding 5 ml of Roswell Park Memorial Institute (RPMI) medium supplemented with 
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10% fetal bovine serum [FBS] and washed using Hank's Salt (HBSS). Cells were then 
resuspended in 5ml of Dulbecco's modified Eagles medium (DMEM), live cells were 
counted using Trypan Blue as a diluent. 
Micro-Neutralization Assay: Influenza specific micro-neutralization assay was 
performed in 96 well plates. Briefly, heat-inactivated human sera were serially diluted 
(1:10 to 1:5120) in serum-free Minimal Essential medium (MEM) in a 96 well plate. Equal 
volume of the two Influenza strains, Influenza A/H1N1/2009/California and Influenza 
A/H3N2/2009/ Perth at 50 TCID50 was added to serum samples and incubated for 1 hour 
at 37°C. After 1 hour, serum-virus mixtures were added to Madin Darby canine kidney 
(MDCK) cells and further incubated for 2 hours at 37°C with 5% CO2. The plates were 
washed and replaced with MEM containing Tosyl phenylalanyl chloromethyl ketone-
modified trypsin after incubation and scored for cytopathic effect after 3 days. The 
highest serum dilution in which 50% of the MDCK cells were intact was scored as the 
neutralization titer. 
ELISA: To measure H1N1/California and H3N2/Perth-specific antibody isotypes, wells of 
Nunc Maxisorp™ plate were coated with 10μg/ml of each virus in bicarbonate buffer 
overnight at 4°C. Isotype standards for IgA1, IgG and IgM (Athens Research & 
Technology, Inc., Georgia, USA) were also included in each plate. After coating, plates 
were washed and blocked with 3%BSA in PBS containing 0.05% Tween. Heat-
inactivated sera of young and old subjects from day 0, 10 and 28 were diluted to 1/250 
and added to the plate for 2h at room temperature, followed by washing 4X with PBST. 
Alkaline phosphatase conjugated mouse anti-human IgA1 at 1:1000, IgG at 1:3000 and 
IgM at1:1000 (SouthernBiotech, Alabama, USA) dilutions were added to the plates and 
incubated for 1h at room temperature. Plates were further washed 4X with PBST and 
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developed using alkaline phosphatase substrate containing pNPP tablets (Sigma 
Aldrich, Missouri, USA) in DEA buffer and absorbance was recorded at 405nm. The 
absorbance values were plotted against standard curves from each plate for every 
isotype and the concentration was determined and is expressed in μg/ml. 
ELISpot Assay: 96 well immobilin-P membrane plates (Millipore, Billerica, MA) were 
coated with 10μg/ml of H1N1 A/California/04/2009 or H3N2 A/Perth/16/2009 virus 
overnight. Negative control (PBS alone) and positive (total human Igs) wells were also 
included. The plates were washed 4X with PBS and blocked with 10% RPMI medium for 
2hrs at 37°C. Freshly isolated PBMCs from human subjects were added onto the plate 
at 2x105 cells/well in duplicates and incubated overnight in a humidified 5% CO2 
incubator at 37°C. The plates were further washed 6X with PBS containing 0.05% 
Tween and incubated with alkaline phosphatase conjugated anti-human IgG (Sigma 
Aldrich, Missouri, USA) at 1:1000 dilution for 1 hrs at 37°C. After the incubation the 
plates were washed 6X with PBST and developed using alkaline phosphatase substrate 
kit (Vector Labs, Burlingame, CA) the spots were analyzed using CTL Immunospot 
(Cellular Technology, Ltd., Cleveland, OH). The spots/well was calculated by subtracting 
spots in negative control wells and normalizing spots to 106 PBMCs cells. 
B cell Detection by Flow Cytometry: 3 x 106 cells of each sample were used for flow 
cytometric analyses. Cells were initially treated with Human TruStain FcX Fc Receptor 
Blocking solution (BioLegend, San Diego, CA) for 30 minutes, washed with PBS at 1500 
rpm for 5 minutes and then stained with fluorochrome-conjugated antibodies. The 
following antibodies were used: CD19-APC-Cy7, CD20-PE (BioLegend), IgD-APC 
CD38-PerCPCy5.5, CD3-Pacific Blue, CD14-Pacific Blue, CD27-FITC, and AmCyan 
Aquablue as a live cell stain. The optimal concentrations of these antibodies were 
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determined experimentally prior to the study. Samples were stained for 30 minutes at 
room temperature, washed with PBS and then resuspended in 150μl of fixative (BD 
Pharmingen). All antibodies were obtained from BD Biosciences (San Jose, CA) unless 
specified differently. The stained samples were analyzed in a LSRII flow cytometer (BD 
Biosciences, San Jose, CA). 
Cells were gated on lymphoid single cells and then on live cells that were negative for 
CD3 and CD14. For ASC identification IgD+ and CD20+ cells were excluded and CD19hi 
cells were gated on CD38hi and CD27hi. In some samples a stain for intracellular IgG 
was included. In these samples CD19hiCD38+ samples upon exclusions of cells 
expressing CD3, CD14, IgD or CD20 were gated onto IgG+ cells. Memory B cells were 
identified by gating on CD19+CD20+CD27+CD38-IgD- cells. Naïve B cells were identified 
by gating onto CD19+CD20+CD27+CD38-IgD+ cells. To detect intracellular IgG, samples 
were stained for extracellular markers, as described above. The cells were then 
permeabilized using Cytofix/Cytoperm (BD Bio-sciences) for 30 minutes at 4°C. Cells 
were washed with Permwash (BD Biosciences) and stained with anti-human IgG-Alexa 
700 (BD Biosciences) with Permwash as a diluent for 30 minutes. Samples were fixed, 
as described above. 
 
 
 
Portions of this chapter were adapted from: 
B cell responses to the 2011/12-influenza vaccine in the aged. Kannan S, Kurupati RK, 
Xiang ZQ, Doyle S, Ratcliffe S, Schmader KE, Ertl HC. Aging (Albany NY). 2013 Mar; 
5(3):209-26. 
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CHAPTER 3 – BTLA EXPRESSION DECLINES ON B CELLS OF THE AGED AND IS 
ASSOCIATED WITH LOW RESPONSIVENESS TO THE TRIVALENT INFLUENZA 
VACCINE 
 
Abstract:  
Virus-neutralizing antibody and B cell responses to influenza A viruses were measured 
in 35 aged and 28 middle-aged individuals following vaccination with the 2012 and 2013 
trivalent inactivated influenza vaccines. Antibody responses to the vaccine strains were 
lower in the aged. An analysis of B cell subsets by flow cytometry with stains for 
immunoregulators showed that B cells of multiple subsets from the aged as compared to 
younger human subjects showed differences in the expression of the co-inhibitor B and 
T lymphocyte attenuator (BTLA). Expression of BTLA inversely correlated with age and 
appears to be linked to shifting the nature of the response from IgM to IgG. High BTLA 
expression on mature B cells was linked to higher IgG responses to the H1N1 virus.  
Finally, high BTLA expression on isotype switched memory B cells was linked to better 
preservation of virus neutralizing antibody titers and improved recall responses to 
vaccination given the following year. 
Introduction/Purpose of study:  
The aims of this study were to measure the expression levels of immunoregulators on 
ASCs, how their expression changed with age, and if expression levels influenced 
antibody responses to TIV.  
Study design:  
35 aged individuals of or above 65 years of age and 28 younger individuals between 30-
40 years of age were enrolled in the Durham-Raleigh-Chapel Hill of North Carolina. 
Briefly, the aged were on average 76 years of age ranging from 66 to 88 years of age, 
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with 64% females and 95% Caucasians. Most individuals but for 4 had been vaccinated 
in 2011, the majority (58%) reported annual vaccinations with TIV. Younger individuals 
were on average 35 years of age with 64% females, 75% Caucasians, 21% African 
Americans and 4% Asians. All but two individuals received the 2011/12 Flu vaccine and 
43% reported annual vaccination to influenza. Some of these individuals were re-
vaccinated the following year with the 2012/13 TIV.  VNA responses were tested against 
the two influenza A virus strains of the vaccine, i.e., H1N1 A/California/7/2009 pdm09-
like virus and H3N2 A/Victoria/361/2011 virus. Immune responses were tested from 
blood at baseline and on days 7 and 14 after TIV. 
Results: 
Younger subjects responded better to the H1N1 vaccine:  
Both cohorts responded to the to H1N1 California//7/2009 (from here on referred to as 
H1N1), but the younger subjects responded better. The younger subjects had higher 
baseline VNA titers to H1N1 (p = 0.0025 by Wilcoxon Rank analysis); titers to H3N2 
Victoria/361/2011 (from here on referred to H3N2) were comparable (Figure 8). After 
vaccination both cohorts developed increased VNA titers to H1N1 and H3N2. VNA 
responses to H1N1 tested at baseline or on days 7 and 14 after vaccination were 
significantly higher in younger than aged individuals (Figure 8A). Responses to H3N2 
virus were also higher in the younger cohort, although this only reached significance for 
day 7 (Figure 8B).   
Younger individuals have more mature B cells:  
The previous chapter showed that mature B cells were significantly lower in the aged 
subjects. In order to verify that this was a consistent observation and to investigate if  
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Figure 8: VNA Responses to Influenza A Viruses. Sera were tested by a 
microneutralization assay on H1N1 California/7/2009 [A], and H3N2 Victoria/361/20011 
[B] virus. Graphs on the top and in the middle show VNA responses of aged and 
younger individuals at baseline and on days 7 and 14 after TIV. Data are shown for 
individual sera, lines show medians ± Interquartile range (IQR). Graphs on the bottom 
show median titers of the two cohorts. (*) Indicates significant differences between titers 
on day 0 compared to days 7 and 14 in graphs that show individual sera calculated by 
Friedman test with Dunn correction with the following p - values: age, H3N2: d7 p = 
0.0013, all other comparisons p < 0.0001. In the graphs showing median titers for both 
cohorts, significant differences between the young and aged indicated by (+) were 
calculated by Wilcoxon matched-pairs signed rank test with the following p-values. 
H1N1: d0 p = 0.0025, d7 p = 0.0038, d14 p = 0.037.  
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other B cell subsets exhibited a similar pattern, we tested for a numbers of different B 
cell subsets by flow cytometry upon staining of PBMCs with antibodies to lineage 
defining markers (Figure 9).  
 
Figure 9: Flow cytometry gating scheme: This figure shows the gating scheme for the 
different B cell subsets, i.e., transitional B cells (CD19+CD20+IgD+CD27+/-CD38+/-), 
mature naïve B cells (CD19+CD20+IgD+CD27-CD38-), non-switched memory B cells 
(CD19+CD20+IgD+CD27+CD38-), switched memory B cells (CD19+CD20+/-IgD-
CD27+CD38,  double-negative B cells (CD19+CD20+IgD-CD27-CD38-) and antibody 
secreting cells. 
 
Numbers of naïve B cells (CD19+IgD+) in blood were at all three time points higher in the 
younger individuals (p < 0.0001) (Figure 10). There was a trend towards increased 
numbers of transitional B cells, which form a link between immature B cells in bone 
marrow and mature naïve B cells in the periphery, in younger individuals; this failed to 
reach significance. The same was seen for double-negative IgD-CD27- B cells, which 
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may reflect exhausted B cells that have previously been described to be more common 
in the aged (49), as well as for switched memory B cells. Numbers of cells within the 
individual subsets were stable over time but for ASCs which in younger and aged 
individuals showed a non-significant trend towards increases on day 7 after vaccination 
as compared to baseline.    
 
 
Figure 10: Circulating B cell subsets: Graphs show the cell counts of different B cell 
subsets, i.e., transitional B cells (CD19+CD20+IgD+CD27+/-CD38+/-), mature naïve B cells 
(CD19+CD20+IgD+CD27-CD38-), non-switched memory B cells 
(CD19+CD20+IgD+CD27+CD38-), switched memory B cells (CD19+CD20+/-IgD-
CD27+CD38,  double-negative B cells (CD19+CD20+IgD-CD27-CD38-) and antibody 
secreting cells. Cell counts are normalized to 106 live PBMCs, with error bars indicating 
Standard Error of the Mean (SEM). **** indicates p-values <0.0001 as calculated by two-
way ANOVA, corrected for multiple comparisons with Tukey. 
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BTLA is significantly lower on aged B cell subsets:  
It has been shown previously for T cells that the expression of co-inhibitors changes 
upon aging (50).  We tested B cells for a number of different markers at baseline and 
upon vaccination, BTLA was found to show significant age-related differences (Figure 
11). 
 
Figure 11: BTLA expression on B cell subsets: Mean Fluorescent Intensity (MFI) of 
BTLA on various B cell subsets at all three time points tested, are shown. Darker 
bars/histograms represent the younger cohort, and the lighter bars/histograms represent 
the aged cohort. Histograms of a representative pair show the MFI intensity on the x-axis 
and events normalized to Mode on the y axis. Within each cell subset, the graph shows 
the MFI with error bars denoting Standard Error of Mean (SEM). (+) within the bars 
indicate statistically significant differences between the two age groups at that time point. 
P-values were calculated using two way ANOVA, corrected for multiple comparisons 
using the Holm-Sidak correction. 
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 At baseline, BTLA expression and percentages of BTLAhi cells were significantly higher 
for B cells of all subsets from younger than aged individuals (Figure 12).  After 
vaccination, expression levels slightly increased on aged B cells while percentages of 
BTLAhi cells increased significantly in the aged for several of the B cell subsets. By day 7 
after vaccination, differences between aged and younger B cells were only significant for 
non-switched memory B cells, switched memory B cells and double-negative B cells. By 
day 14 after vaccination, both levels of BTLA expression and percentages of BTLAhi 
cells became comparable for all B cell subsets between the two age groups. 
 
Figure 12: Percentage of BTLAhigh cells is lower in the aged: Figure shows the % of 
cells that were BTLAhi over the parental population. (+) within the bars indicate 
statistically significant differences between the two age groups at that time point. (*) 
above the bars indicate statistically significant differences within the same age group, 
between different time points as indicated by the lines. p-values were calculated using 
two way ANOVA, corrected for multiple comparisons using the Holm-Sidak correction. 
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BTLA expression at baseline showed a strong negative correlation with the biological 
age of the individuals on all B cell subsets again supporting that declines in expression 
of the co-inhibitor are age-related (Figure 13A). 
 
Figure 13: Correlation of BTLA expression with age and BTLA related increases in 
antibody titers:  A shows the r- values of correlation of BTLA Mean Fluorescent 
Intensity (MFI) with age, as calculated by nonparametric Spearman correlation. All p-
values were highly significant (<0.00001). Mature naïve: p=0.00008; Non Switched 
Memory: p=7.89e-7; Transitional: p=0.00066; Double negative: p=0.00002; Switched 
memory: p=2.21e-6; ASC: p=0.00053.  
B shows the mean (±SEM) increases in antibody titers to the H1N1 influenza virus, in 
individuals with either high BTLA on their mature B cells (BTLA high) shown in dark grey 
or low BTLA on their mature B cells (BTLA low) shown in light grey. * indicates statistical 
significance (p<0.05) as calculated using the Mann Whitney test. p=0.028 for IgG. 
p=0.035 for IgM. Antibody titers were measured by ELISA. 
 
BTLA expression on mature B cells is linked to higher increases in antibody titers:  
To see if BTLA expression was related to antibody production, we looked at antibody 
titers of individuals with either high or low levels of BTLA on their mature B cells. We 
tested this in an age independent manner, to remove the age bias as the focus of the 
question was on the link between BTLA and antibody production, irrespective of age. We 
selected ten individuals who had either the highest (BTLA high) or lowest (BTLA low) 
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expression on their mature B cells, at baseline/, and looked at their virus specific 
antibody titers by ELISA, at baseline and two weeks after vaccination. Individuals with 
high BTLA on their mature B cells, showed a higher increase in IgG antibodies to the 
H1N1 virus, compared to those with low BTLA on their mature B cells (Figure 13B). This 
trend was reversed for IgM titers, indicating a possible role for BTLA in class switching of 
antibody responses.  
Follicular T helper cells express the binding partner of BTLA:  
 To more formally test if BTLA signaling might affect induction or functions of ASCs we 
tested if HVEM, the binding partner of BTLA, is expressed on follicular T helper (TFH) 
cells. TFH cells interact with B cells during their differentiations into ASCs in lymph node 
follicles through bindings between PD-1 and PD-L2 (51) or ICOS and ICOS-ligand (52) 
expressed on TFH and B cells, respectively. TFH cells, which generally reside in lymph 
nodes, can be detected at low frequencies in blood (53). They were identified by positive 
staining for CD4, CXCR5 and PD-1. B cells were identified by staining for CD19. A stain 
for BTLA was included in the experiment, which used PBMC samples from 13 aged and 
6 younger individuals that were not part of the original cohort shown in Figures 8-13. As 
shown in Figure 14, BTLA was expressed at high levels on B cells while TFH cells were 
BTLAlo. Results from this new cohort again confirmed higher BTLA expression on B cells 
from younger individuals. This was also seen for TFH cells. HVEM was expressed at 
approximately equal levels on TFH cells between the younger and the aged individuals, 
while B cells from younger individual expressed slightly higher levels. Overall these 
results indicated that BTLA on B cells could interact with its binding partner HVEM on 
TFH cells. This in turn together with or in place of other receptor-ligand interaction may 
transfer of signals from TFH to B cells. 
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Figure 14: BTLA and HVEM expression on B cells and TFH cells. Graphs show the 
MFI of BTLA and HVEM on CD19+ B cells and CD3+CD4+CXCR5+PD-1+ TFH cells, with 
error bars showing SEM. Dark grey bars are show data from younger subjects, and light 
grey bars aged subjects. (*) within bars, indicate statistical significance (p<0.05) between 
the young and aged cohorts, within that cell subset. P-values were calculated using 
multiple t-tests, corrected for multiple comparisons with Holm-Sidak correction. On B 
cells: p=0.002; BTLA on Tfh cells: p=0.001; HVEM on B cells: p=0.023 
Histograms show BTLA or HVEM expression on B and Tfh cells of a representative 
young subject. The solid black line histogram shows the respective MFI on B cells and 
the dotted grey line histogram shows TFH cells.  HVEM MFI. Both histograms show 
intensity on x-axis and Events normalized to Mode on the y-axis. 
 
High BTLA expression on memory B cells influences VNA responses: 
Many of the individuals that we vaccinated in the 2012/13 season were vaccinated again 
by our team in the 2013/14 season. This gave us the opportunity to follow the evolution 
of antibody titers after an additional boost. To assess if levels of BTLA expression in 
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2012/2013 influenced VNA responses to the two influenza A virus strains of the vaccine 
in 2013/2014 we selected 10 individuals (regardless of age) that at baseline in 2012 had 
the highest (4 aged, 6 younger) or lowest (9 aged, 1 younger) levels of BTLA expression 
on their switched memory B cells. We analyzed their VNA titers on days 0, 7 and 14 
after vaccination with 2012/13 TIV and then again 1 year later on day 0, 7 and 28 in 
relation to the 2013/14 dose of TIV. Increases in VNA titers to the influenza A virus 
strains of TIV in 2012 were similar in individuals with BTLAhi or BTLAlo switched memory 
B cells although there was an insignificant trend towards higher responses of the former 
to H3N2 virus. More impressive was that individuals with BTLAhi switched memory B 
cells maintained higher titers of H1N1 and H3N2-specific VNAs for the one year period 
between their seasonal Flu shots (compare d0 levels in 2013) and in addition mounted 
more robust recall responses in the following season compared to those that had BTLAlo 
switched memory B cells at baseline in 2012 (Figure 15).  
 
Figure 15: Correlation of BTLA expression and VNA responses.  Graphs shows 
VNA titers over time of selected patients with either BTLAhi or BTLAlo switched memory 
cells (as determined at baseline 2012). The x-axis shows the dates of vaccination and 
follow-up over the two consecutive years of vaccination. Statistically significant 
differences are indicated by (*) with the following p-values: Response to H1N1 2013 d7: 
p=2.55e-5; d28: p=0.003; Response to H3N2 2013 d7: p=6.025e-6; d28: p=0.0009. 
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The goal of this study was to measure the expression of immunoregulators on ASCs and 
how they changed with age. I successfully achieved that with this study, showing a 
decline in BTLA expression on B cells upon immunosenescence that may be linked to 
decreased induction of long-lived plasma cells, memory B cells, and antibody titers in the 
aged. 
Discussion:  
The aims of this study were to measure the expression levels of immunoregulators on 
ASCs, study how their expression changed with age, and assess if and how they 
influenced antibody responses to the 2012-13 TIV. A cohort of middle-aged individuals 
was chosen for comparison to the elderly under the expectation that these subjects also 
had previous although less numerous exposures to influenza viruses or vaccines. 
Antibody responses were analyzed to identify non-responders by neutralization assays. 
As expected antibody responses of the aged tended to be lower than those of younger 
individuals.  
My main emphasis was to identify differences in B cell subsets at baseline and upon 
immunization between aged and younger individuals and to assess if and how the 
differences may relate to low responsiveness of the aged. Confirming previous results, 
numbers of circulating naïve B cells were lower in the aged (54) while numbers of some 
of the other subsets only showed a trend towards an age-related decline. The other 
major finding from this study was the decreased expression of BTLA on aged B cells, 
and its possible role in the lowered virus neutralizing antibody responses to the TIV.  
The key finding in this study was the decrease in expression of BTLA levels on various B 
cell subsets upon aging. BTLA binds to HVEM, but not exclusively. HVEM can also bind 
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CD160, LIGHT and lymphotoxin A (55). BTLA and CD160 bind to overlapping sites while 
LIGHT and lymphotoxin B bind to a different domain.  CD160 and BTLA provide 
inhibitory signals while LIGHT and lymphotoxin A act as co-stimulators, with negative 
signaling prevailing in the case of simultaneous binding. The BTLA signaling pathway 
has mainly been studied for T cell responses where its blockade was shown to increase 
T cell responses to vaccines (56) and resistance to infections (57). Negative signaling 
through BTLA seems to be conserved in CD8+ T cells of aged mice as gD-mediated 
blockade markedly improves their response to vaccination (58).  
Downstream events of BTLA, a member of the CD28 family, remain controversial. The 
cytoplasmic tail of BTLA similar to that of the well characterized PD-1 immunoregulator 
carries a membrane proximal immunoreceptor tyrosine-based inhibition motif (ITIM) and 
a membrane distal immunoreceptor tyrosine-based switch motif (ITSM). These motifs 
through recruitment of the Src homology (SH) proteins (SHP)-1, and SHP -2 could inhibit 
the activating effects of CD3/CD28 ligation leading to reduced production of cytokines 
and cell proliferation (59). BTLA also contains a sequence in its cytoplasmic domain that 
may interact with the Grb-2 adaptor protein and either directly or indirectly with the p85 
subunit of PI3 kinase, which in turn could provide survival signals (60). Indeed although 
BTLA is generally viewed as a co-inhibitor one report showed that this may depend on 
the strength of antigenic stimulation, - specifically in the setting of cardiac allograft 
rejection - where BTLA was found to have an inhibitory role in weak alloantigen 
stimulation, while upon potent alloantigen stimulation BTLA appeared to promote the T 
cell response (60). Other data showed that lack of BTLA reduced rather than augmented 
pathology in a colitis model (61) and promoted survival of antigen-specific CD8+ T cells 
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induced by bacterial infection (62) again suggesting that BTLA may have disparate roles 
in maintaining homeostasis of the immune system. 
An interesting observation was the relationship between BTLA expression on mature B 
cells prior to vaccination, and increases in H1N1-specific IgG antibody titers with 
concomitant decreases in IgM titers. This seems to indicate that high BTLA expression 
on mature B cells might play a role in augmenting IgG production, specifically in shifting 
the response from IgM to IgG. The fact that we only saw this for the H1N1 virus, and not 
the H3N2 virus needs to be noted. It may reflect that H1N1 underwent a dramatic 
change in 2009 and is thus a fairly recent virus while variants of H3N2 have been 
circulating since 1968. 
Another intriguing observation from this study was the high expression of BTLA on 
switched memory B cells, the main subset that responds to vaccination against influenza 
virus to which adult humans in general have immunological memory, was linked to better 
preservation of VNA responses to the two influenza A virus strains of TIV and to higher 
recall responses upon the next dose of TIV given one year later. This in turn suggests 
that BTLA may promote rather than suppress the induction of long-lived plasma cells 
and memory B cells, a hypothesis that remains to be investigated further.  
The goal of this study was to measure the expression of immunoregulators on ASCs and 
how they changed with age. I successfully achieved that with this study, showing a 
decline in BTLA expression on B cells upon immunosenescence that may be linked to 
decreased induction of long-lived plasma cells, memory B cells, and antibody titers in the 
aged. 
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Materials and methods:  
 
Virus strains: The two influenza A vaccine strains of the 2012/13 seasonal influenza 
vaccine, A/California/7/2009 (H1N1) pdm09-like virus and A/Victoria/361/2011 (H3N2)-
like virus were obtained from the Center for Disease Control, Atlanta, Georgia. Viruses 
were expanded by injecting 100 µl of 4 hemagglutinating units (HAU) of virus/ml into 10 
day-old specific pathogen-free embryonated eggs, which were then incubated for 48 hrs 
at 35°C. After 48 hrs, the eggs were chilled at 4°C overnight. The allantoic fluids from the 
infected eggs were harvested and concentrated by centrifuging at 20,000rpm for 1 hour 
at 4°C. The concentrated viral pellet was resuspended in PBS and further purified by 
fractionation over 10-55% sucrose density gradients at 25,000rpm for 2 hrs. Purified 
viruses were serially diluted on Madin-Darby Canine Kidney (MDCK) cells to determine 
mean tissue culture infective dose (TCID50) after 3 days of infection by screening for 
cytopathic effects (CPE). 
Human subjects: Blood was collected after informed consent from community dwelling 
persons in the Durham-Raleigh-Chapel Hill area of North Carolina. Younger individuals 
were 30-40 years of age; older individuals were > 65 years of age. The following 
subjects were excluded from the study: (1) humans with immunosuppression resulting 
from diseases (e.g., clinically active malignancy, HIV/AIDS, immune disorders) or drugs 
(e.g., cancer chemotherapy, corticosteroid use); (2) individuals with significant 
underlying diseases that would be expected to prevent completion of the study; (3) 
subjects, which were bed-ridden or homebound or had intercurrent illnesses that might 
interfere with interpretation of study (e.g., urinary tract infection, respiratory tract 
infection); (4) individuals that were unlikely to adhere to protocol follow-up; (5) subjects 
that were involved in a conflicting study; (6) subjects that had a history of alcohol or 
52 
 
substance abuse; (7) subjects with contraindication for influenza vaccination such as 
anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine, 
and moderate or severe acute illness with or without fever, and Guillain-Barre Syndrome 
within 6 weeks following a previous dose of influenza vaccine. Persons with moderate to 
severe acute febrile illness were not vaccinated until their symptoms had abated. 
From enrolled subjects demographic data and medical history including medical 
diagnoses, medications, vaccination to influenza and other infectious diseases, and 
history of influenza or influenza-like diseases during the last 5 years were recorded. 
Subjects were bled and then vaccinated with TIV via the intramuscular route in the 
deltoid muscle. Subjects were bled again on days 7 and 14 following injection of TIV. 
Some of the subjects were revaccinated with TIV the following years using the same 
procedures. 
Collection of blood and isolation of PBMCs and plasma: Blood was collected into 
heparinized tubes and shipped overnight to Philadelphia, PA. A 1.5 ml aliquot of each 
sample was set aside for serum collection. PBMCs were isolated from the remaining 
samples using established protocols. Specifically, blood was overlaid onto Ficoll-Paque 
Plus (GE Healthcare Biosciences, Piscataway Township, NJ) and spun for 30 minutes at 
2000 rpm, with brake off, and at 50% acceleration. The PBMC layer at the Ficoll 
interface was then collected and washed twice with Hank’s Balanced Salt Solution 
(Gibco, Grand Island, NY), by centrifuging at 2000 rpm. The washed, pelleted cells were 
treated with 10 ml of red blood cell lysis buffer (eBioscience, San Diego, CA). Lysis was 
stopped by adding 5 ml of Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% fetal bovine serum [FBS]. Cells were washed with Hank’s Salt 
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(HBSS). Cells were resuspended in 5ml of Dulbecco’s modified Eagles medium 
(DMEM), live cells were counted using Trypan Blue as a diluent. 
Micro-neutralization assay: Two-fold serially diluted (1:20 to 1:10240) heat-inactivated 
human sera were tested for neutralizing antibodies to influenza A virus strains by micro-
neutralization assays. Equal volume of 100TCID50 per well of the titrated virus was 
added to the diluted serum in 96 well plates and incubated at 37°C. After 1hr, serum-
virus mixtures were added to MDCK cells that had been washed twice with serum-free 
Dulbecco’s Modified Eagles Medium (DMEM). The cells were incubated for 2 hrs at 
37°C with 5% CO2. The cells were washed and re-incubated with DMEM supplemented 
with L -1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK) trypsin for 3 days. 
CPEs were scored under a microscope. Neutralization titers were defined as the dilution 
of the serum that resulted in 50% inhibition of CPE formation. 
B cell detection by flow cytometry: Each subject sample was initially treated with 
Human TruStain FcX Fc Receptor Blocking solution (BioLegend, San Diego, CA) for 30 
minutes, washed with PBS at 1500 rpm for 5 minutes and then stained with 
fluorochrome-conjugated antibodies. Samples were stained first for their extracellular 
markers using the following antibodies: CD19-Brilliant VioletTM 650, CD20- Brilliant 
VioletTM570, IgD-PeCy7, CD38-PerCPCy5.5, CD3-Pacific Blue, CD14-Pacific Blue, 
CD27-FITC, BTLA-APC, and AmCyan Aquablue as a live cell stain. The optimal 
concentrations of these antibodies were determined experimentally. Samples were 
stained for 30 minutes at room temperature and washed with PBS. The cells were then 
permeabilized using Cytofix/Cytoperm (BD Biosciences) for 30 minutes at 4°C, washed 
with Permwash (BD Biosciences) and stained with their specific panel of intracellular 
antibodies. The samples were stained with the intracellular stains for 30 minutes at 4°C, 
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washed with PBS and then resuspended in 150μl of fixative (BD Pharmingen). All 
antibodies were obtained from BD Biosciences (San Jose, CA) unless specified 
differently. The stained samples were analyzed in a LSRII flow cytometer (BD 
Biosciences, San Jose, CA). 
ELISA: H1N1- and H3N2-specific binding antibody isotypes were measured by ELISA. 
Briefly, wells of Nunc Maxisorp™ plate were coated with 10μg/ml of influenza H1N1 or 
H3N2 virus along with isotype standards for IgA1, IgG and IgM (Athens Research & 
Technology, Inc., Georgia, USA) in bicarbonate buffer overnight at 4°C. The plates were 
blocked with 3% BSA in PBS and incubated for 2 hrs at room temperature with heat-
inactivated sera of young and aged subjects at a dilution of 1/250. The plates were 
washed 4X with PBS containing 0.05% tween (PBST) and incubated for 1 hour at room 
temperature with alkaline phosphatase conjugated mouse anti-human IgA1 at 1:1000, 
IgG at 1:3000 and IgM at 1:1000 dilutions (SouthernBiotech, Alabama, USA). Following 
the incubation, plates were washed 4X with PBST and developed using alkaline 
phosphatase substrate containing pNPP tablets (Sigma Aldrich, Missouri, USA) 
dissolved in DEA buffer. Adsorbance was recorded at 405nm. The adsorbance values 
were plotted against standard curves from each plate for every isotype. Antibody 
concentrations were determined and are expressed in μg/ml. 
 
 
 
Portions of this chapter were adapted from: 
BTLA expression declines on B cells of the aged and is associated with low 
responsiveness to the trivalent influenza vaccine. Kannan S, Kurupati RK, Doyle SA, 
Freeman GJ, Schmader KE, Ertl HC. Oncotarget. 2015 Aug 14; 6(23):19445-55. 
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CHAPTER 4: B CELL IMMUNOSENESCENCE IN MICE: CHANGES IN GENE 
EXPRESSION PROFILES, EXPRESSION OF IMMUNOREGULATORS AND 
METABOLISM 
Abstract:  
I analyzed age-related defects in B cell populations from young and aged mice. 
Microarray analysis of bone marrow resident antibody secreting cells (ASCs) showed 
significant changes upon aging, affecting multiple genes, pathways and functions 
including those that play a role in immune regulation, humoral immune responses, 
chromatin structure and assembly, cell metabolism and the endoplasmic reticulum (ER) 
stress response. Aged ASCs expressed higher levels of immunoregulators including PD-
1. Increased PD-1 expression was also seen on mature aged B cells indicating early 
defects in the lineage. High PD-1 expression on the aged ASCs correlated with high 
cellular reactive oxygen species levels. Mitochondrial defects in aged B cells were 
demonstrated by the absence of an increases in basal respiration observed upon in vitro 
stimulation of young B cells. 
Introduction/Purpose of study:  
While the previous chapters addressed the effect of aging in the human immune system, 
the aim of this study was to study how immunosenescence in mice – with the overall 
hypothesis that expression levels of immunoregulators on ASCs change upon aging, 
and that aged ASCs are metabolically different compared to the younger and that 
changes in immunoregulators are linked to metabolic defects or vice versa.   
Here I further elucidated in mice the age-related defects in B cell populations. Whole 
genome expression arrays comparing bone marrow-derived ASCs from young and aged 
mice showed disparity of expression in over 2000 probes and distinct clustering. Genes 
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that were differentially expressed participate in numerous pathways and functions 
including immunological and metabolic functions. Aged B cells have increased levels of 
ROS and show differential expression of immunoregulators such as PD-1. Expression of 
PD-1 in turn is strongly correlated with levels of cellular (c) ROS. Defects in 
mitochondrial functions were demonstrated upon in vitro stimulation of B cells.  
Results: 
 
ASCs and their precursor populations are decreased in aged mice 
Previous studies have shown that bone marrow output of naïve B cells is decreased 
upon aging (63). So, the first goal was to measure the number of ASCs in the spleens 
and bone marrow of young and aged mice using multicolor flow cytometry (Figure 16). 
ASCs were significantly reduced in the aged mice in both the bone marrow and the 
spleen – the two primary reservoirs for ASCs (Figure 17). The reduction was especially 
pronounced in the bone marrow, suggesting either reduced generation of long-lived 
ASCs or a decline in their life span. 
In order to see if this discrepancy in ASC numbers was a remnant of a difference in their 
precursor population, we enumerated mature B cells and CD23+ B2 cells. We noticed 
significantly lower percentages of mature B cells and CD23+ B2 cells in the aged mice 
(Figure 18). This corroborates previous observations showing that bone marrow output 
of naïve B cells is decreased upon aging.  
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Figure 16: Gating strategy for ASCs: Figure shows the gating strategy used to identify 
ASCs (Antibody Secreting Cells) – CD3- CD14- Live IgD- CD19+ CD138+ Intracellular 
IgG+. A representative young mouse sample is shown.  
      
Figure 16: Aged mice have lesser ASCs. Figure shows numbers of ASCs in the 
spleen and bone marrow of young and aged mice. Aged mice are shown in black 
columns and young mice in grey columns. * denotes significance by t tests with Mann 
Whitney correction (ASCs in bone marrow: p=0.0012; ASCs in spleen: p=0.03) 
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Figure 18: Aged mice have lower frequencies of mature B cells. Figure shows 
frequencies of mature B cells and CD23+ B2 B cells. Aged mice are shown in black 
columns and young mice in grey columns. * denotes significance by t tests (Frequencies 
of mature B cells: p=0.0079; CD23+ B2 B cells: p=0.0079). 
 
Microarray analysis of ASCs shows multiple differences in transcriptome:  
To elucidate age-related changes in ASCs, I isolated bone marrow resident ASCs from 
12 young and 10 aged mice by cell sorting and profiled whole genome cDNA expression 
using Illumina Bead Arrays.  I tested cells from individual mice or if cell numbers were 
low from pooled samples, resulting in 9 unique young samples and 6 unique aged 
samples. The aim of these experiments was to compare cells at the gene expression 
level and identify differently expressed genes, pathways and functions. The data was 
submitted to GEO database (http://www.ncbi.nlm.nih.gov/geo/) under accession number 
GSE72224.   
A total of 2175 probes were differentially expressed in ASCs from young mice compared 
to aged mice, at a p-value of 0.05.  Of these probes, 1411 (65%) were more highly 
expressed in the aged mice while 764 (35%) had higher expression in the young mice. 
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Principle component analysis using 715 (p < 0.01) gene probes showed that young and 
aged ASCs clustered as 2 well separated groups (Figure 19).  
 
Figure 19: Principal component analysis: Figure shows clustering of genes significant 
at a p-value of 0.01 along the first two principal components. 
 
A heatmap of the expression of the 100 genes that were the most significantly 
differentially expressed (by p-value) between the two groups is shown in Figure 20. 
Using Ingenuity Pathway Analysis, a number of functions distinguished the aged mice 
from the young mice. The most significant differences were observed for cell death and 
survival, cellular growth and proliferation, hematological system development and 
function, tissue morphology, cellular development, humoral immune response and 
protein synthesis.  
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Figure 20: Heatmap of the top 100 genes that are differentially expressed between 
young and aged ASCs. Transcript names are shown along the right axis.  Red: 
increased expression, blue: decreased expression. 
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Immunoregulators: Transcripts for a number of immunoregulators including CD 
markers, interleukin receptors, natural killer cell receptors and members of the TNF 
family were differentially expressed in aged and young ASCs (Figure 21).  
 
Figure 21: Differences in the expression of transcripts that encode 
immunoregulators between young and aged ASCs. Positive numbers show higher 
expression in the aged ASCs, negative numbers show high expression in young ASCs. 
 
Most were higher in the aged (19/24). Several are known to affect B cell fate decisions. 
BACH2, which is essential for class switching, was expressed higher in young ASCs. 
XBP1, which becomes crucial at late stages of plasma cell development, was higher in 
aged ASCs. IRF4 and IRF8 were also differentially expressed; the former was 
overexpressed and the latter under expressed in aged B ASCs. Both play critical non-
redundant roles in plasma cell development and germinal center formation. IRF8 
induces expression of Bcl6. IRF4 down-regulates Bcl6 and instead induces Blimp-1 
62 
 
encoded by the PRDM1 gene. Transcripts for PRDM1 were increased in aged ASCs. 
While Bcl6 promotes germinal center formation and proliferation of B cells Blimp-1 drives 
terminal differentiation of plasma cells. These data support reduced class-switching in 
aged B cells and more terminal differentiation of aged plasma cells. 
IPA also showed significant (p ≤ 0.01) differences in ATM and p53 signaling and antigen 
presentation (Figure 22). Most of the differentially expressed transcript encoding 
proteins involved in ATM signaling, which is activated by double-stranded DNA breaks, 
were higher in young mice (5/7) while transcripts for proteins of the p53 pathway were 
more commonly high in aged cells (5/8). Transcripts for antigen presentation pathways, 
such as those encoding histocompatibility antigens, were also higher in aged ASCs.  
 
 
Figure 22: Differences in the expression of genes in the most significantly altered 
canonical pathways identified using Ingenuity. Positive numbers show higher 
expression in the aged ASCs, negative numbers show high expression in young ASCs. 
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Enrichment of genes involved in the humoral immune responses (Figure 23) were 
identified by Ingenuity Pathway Analysis (IPA), and again most of the involved genes 
had higher expressed in aged ASCs.   
 
Figure 23: Differences in the expression of genes involved in the humoral immune 
responses biological function identified using Ingenuity. Positive numbers show 
higher expression in the aged ASCs, negative numbers show higher expression in 
young ASCs. 
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Metabolism and metabolic disorders: Differences in metabolic diseases, carbohydrate 
and lipid metabolism were also observed (Figure 24). Most transcripts for metabolic 
disorders (42/55), carbohydrate (19/22) and lipid (4/4) metabolisms were expressed at 
higher levels in aged as compared to young ASCs.  
 
Figure 24: Differences in the expression of genes involved in metabolic disorders 
(on the left) or lipid and carbohydrate metabolism (right) identified using 
Ingenuity. Positive numbers show higher expression in the aged ASCs, negative 
numbers show high expression in young ASCs. 
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Several other genes involved in lipid and carbohydrate metabolism were also 
differentially expressed between young and aged ASCs at a more lenient p-value 
threshold of 0.05 and without fold change restrictions.  
 Another interesting observation was the differences in expression seen in mitochondrial 
proteins encoding components of the electron transport chain (Figure 25), and 
mitochondrial fission (FIS1), which affects mitochondrial morphology (64). These 
transcripts were more highly expressed in aged ASCs.  One mitochondrial ribosomal 
protein [MRLP33 (-1.59)] and one key ATP synthase [ATP5j (-1.48)] were under 
expressed in aged ASCs.  
 
Figure 25: Differences in the expression of genes involved in the electron 
transport chain. Positive numbers show higher expression in the aged ASCs, negative 
numbers show higher expression in young ASCs 
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Functional analysis by DAVID: Database for Annotation, Visualization, and Integrated 
Discovery - (65) showed significant differences in expression levels for the endoplasmic 
reticulum with most genes having higher expression in the aged (51/52). At a lower 
significance threshold (genes with p < 0.05), transcripts indicative of ER stress were 
increased in the aged (5/5) while those involved in protein folding were in part higher in 
the younger (4/10).  (Figure 26).  
 
Figure 26: Differences in the expression of genes involved in the Endoplasmic 
Reticulum (ER), ER stress and Protein folding:  Positive numbers show higher 
expression in the aged ASCs, negative numbers show higher expression in young ASCs 
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Differences were also seen in genes controlling functions of peroxisomes, which are 
involved in fatty acid metabolism and reduction of ROS. These included VCP (1.61), 
involved in assembly of peroxisome (66), PPARD (1.24), a regulator of energy 
metabolism (67) and ACBD5 (1.27), a peroxisome receptor for acyl-CoA-esters (68). 
We selected a number of immunoregulators that were differentially expressed in the 
microarray, and measured their protein levels by flow cytometry. Flow cytometry analysis 
confirmed differences that were observed at the transcriptome level. Mainly, CD52 and 
CD98 were significantly higher on the aged ASCs (Figure 27).  
 
Figure 27: Expression levels of CD52 and CD98 on bone marrow derived ASCs 
from young and aged mice. Graphs on the left show Mean Fluorescent Intensity (MFI) 
of the specified molecule. Samples from aged mice are in black, and from young mice in 
grey. Error bars represent standard error of the mean (SEM). Representative histograms 
are shown on the right.  Samples from aged mice are shown with a solid black line. 
Samples from young mice are shown in grey. * denotes significant differences as 
determined by Mann-Whitney test. (CD52: p=0.0079; CD98: p=0.005) 
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PD-1 expression is higher on aged ASCs: 
The microarray analysis had indicated that immunological and metabolic pathways were 
both changed upon aging in ASCs. PD-1 is an immunoregulator that has been shown to 
have significant metabolic functions by inhibiting glycolysis in activating T cells (26). To 
assess if PD-1 plays a potential role in regulating metabolism in ASCs, we measured its 
expression levels and observed that PD-1 levels were significantly higher on aged 
ASCs, a difference that was also observed on mature naïve B cells (Figure 28). 
 
Figure 28: PD-1 expression on mature B cells and ASCs. Graphs on the left show 
the MFI of PD-1 expression, with error bars representing SEM. Aged samples are shown 
in black and the young in grey. Representative histograms are shown alongside with the 
aged samples in a solid black line and the young samples in grey. * denotes significant 
differences as determined by Mann-Whitney test. (Mature B cells: p=0.0079; ASCs: 
p=0.0159) 
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Aged ASCs have high cellular ROS levels, which correlate with PD-1 expression: 
Since PD-1 plays a role in cellular metabolism of T cells and is expressed higher on 
aged B cells, we tested splenic ASCs for metabolic parameters and found that they carry 
higher levels of cROS, indicative of increased oxidative stress compared to cells from 
young mice (Figure 29A). ROS is produced within cells by numerous pathways with 
major sources being the mitochondrial electron transport chain, peroxisomes and the 
endoplasmic reticulum (ER) (69; 70; 71). Peroxisomes, which play a central role in lipid 
metabolism, contain a number of ROS producing and detoxifying enzymes. As 
mentioned previously, genes that control peroxisome assembly and size were 
differentially expressed between ASCs of the two age groups. During oxidative protein 
folding, ROS such as H2O2 is produced in the ER. Accumulation of misfolded proteins 
triggers an ER stress response (72) to reduce protein production, enhance production of 
chaperones that assist in protein folding, increase production of enzymes that ubiquinate 
and degrade misfolded proteins and initiate apoptosis.  
Two enzymes that participate in cytoplasmic, peroxisomal and mitochondrial ROS 
metabolism were higher in the aged. These were PRDX4 (1.85) (73), which reduces 
hydrogen peroxide to water and CCS (1.25) (74), a copper chaperone for superoxide 
dismutase (SOD), a key group of enzymes that destroy ROS in the cytoplasm, 
mitochondria and peroxisomes. During oxidative protein folding, ROS such as H2O2 is 
produced in the ER. Accumulation of misfolded proteins triggers an ER stress response 
(72) to reduce protein production, enhance production of chaperones that assist in 
protein folding, increase production of enzymes that ubiquinate and degrade misfolded 
proteins and initiate apoptosis.  
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Levels of cellular ROS in ASCs correlated with PD-1 expression indicating a link 
between the immunoregulator and metabolism (Fig. 29B).   
 
Figure 29: cROS expression is higher on aged ASCs and correlates with PD-1 
expression. A shows cROS levels in young and aged ASCs. Samples from aged mice 
are shown in black and from younger mice in grey. Graph on left shows MFI, with error 
bars indicating standard error of the mean. * denotes significant differences as 
determined by Mann-Whitney test. (p=0.0079). B shows the positive correlation between 
cROS and cell surface expressed PD-1 using ASC samples from young and aged mice. 
Correlation was determined by Spearman. R and p-values are shown within the graphs. 
 
Aged B cells upon activation exhibit defects in mitochondrial respiration:  
The arrays indicated marked differences in carbohydrate and lipid metabolism as well as 
in the electron transfer chain between ASCs from young and aged mice. To further 
assess metabolic differences I tested bead purified resting and mitogen-stimulated B 
cells from young and aged mice for basal respiration and lactate production by Seahorse 
XF flux analyzer (75) (Figure 30). Aged resting B cells showed higher oxygen 
consumption rates (OCR), which mainly measures oxidative phosphorylation (OXPHOS) 
through the electron transfer chain. In addition, there were higher extracellular 
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acidification rates (ECAR), as a measure of lactate production by glycolysis, in B cells of 
aged mice compared to young B cells, suggestive of higher metabolic activity of aged 
compared to younger B cells. The OCR to ECAR ratio was slightly higher in younger B 
cells indicating a higher contribution of OXPHOS to their overall energy production.    
 
Figure 30: Defects in mitochondrial respiration: OCR and ECAR as well as ratios of 
OCR/ECAR are shown upon measuring splenic B cells without stimulation (top panels) 
or after stimulation for 6 or 24 hours (lower panels).Columns with vertical lines indicate 6 
hour time points. Lines indicate significant differences between groups calculated by t-
tests or 1-way ANOVA. * p values between 0.01 – 0.05, ** p-values between 0.001 – 
0.01, *** p-values between 0.0001 – 0.001, **** p – values < 0.0001. 
 
B cells were then stimulated with a cocktail of mitogens and tested 6 or 24 hours later. 
After 6 hours OCR and ECAR remained comparable to those of unstimulated young and 
old B cells. After 24 hours OCR markedly increased in younger but not aged B cells, 
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while ECAR increased in both. These data indicate that upon aging, OXPHOS cannot 
satisfy increases in energy demands under challenging conditions.  
In summary, the goal of this study was to investigate the effect of immunosenescence on 
ASCs – specifically characterize immunoregulator expression and elucidate if aged 
ASCs were metabolically different from the younger. I achieved this with this study 
showing that bone marrow-derived ASCs, which are generated throughout a lifespan of 
an individual, show substantial differences in their gene expression profile in aged as 
compared to young mice, which may underlie their deteriorating functions. We also 
showed the increased expression of PD-1 on aged ASCs and its correlation with high 
levels of cellular ROS levels. This is a link that needs to be studied further.  
Discussion:  
 
The aim of this study was to further elucidate the effect of immunosenescence on ASCs. 
I started by using microarrays to identify age-related changes in ASCs from bone 
marrow where most long-lived plasma cells reside.  
As expected, many genes involved in numerous pathways and functions were 
differentially expressed between young and aged ASCs. The first one of interest is ATM 
signaling. Upon aging, cells accumulate DNA mutations, which may lead to structural 
changes of DNA (28). Our array data show reduced ATM signaling in the aged. The 
ATM pathway is induced by DNA damage; it prevents cells from progressing through the 
cell cycle, and can increase DNA repair mechanisms or drive cells to undergo apoptosis 
(76). ATM regulates apoptosis through p53, a pathway, which was also affected in aged 
ASCs. Reduced ATM signaling in turn could contribute to increased lasting DNA 
damage. An analysis of differences in significant biological functions accordingly showed 
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the most significant differences for cell survival and death and cell growth and 
proliferation. Although it is assumed that long-lived bone marrow derived plasma cells 
are terminally differentiated, and thereby incapable of proliferation, recent gene 
expression array analyses indicate that although bone marrow-derived ASCs are 
quiescent they are capable of undergoing some replicative cell renewal (77). Reduced 
proliferation in the aged combined with increased rates of apoptosis could thus explain 
the marked reduction of numbers of ASCs especially of those residing in the bone 
marrow.   
Ingenuity analysis for significant functions also revealed differences in humoral immune 
responses. Four of the 13 genes with lower expression in the aged play a role in DNA 
recombination or generation of antibody diversity confirming previous studies that upon 
aging antibody responses lose breadth (78).  
Another interesting observation was the differential expression of transcripts for the ER 
stress response. Previous studies showed that the ER stress response also referred to 
as the unfolded protein response increases in the aged due to loss of chaperone 
proteins (79). This increases apoptosis and may contribute to the reduced numbers of 
ASCs. This increased susceptibility for ER stress and unfolded proteins could also 
contribute to increases in ROS, which can have an effect on the metabolism of the cell.  
Aging can impair cellular metabolism in mice in multiple ways. Two reasons are 
increased resistance to insulin (80) and deleterious alterations of mitochondria caused, 
for example, by the disorganization of their structure (81). This latter cause is evidenced 
in our array data by the increase in expression of FIS1, which regulates mitochondrial 
fission and thereby affects mitochondrial morphology. Upon aging, mutations also 
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accumulate in mitochondrial DNA4, along with ROS increases (82), which again was 
recapitulated in our studies. Mitochondria then lose the ability to efficiently generate 
energy through OXPHOS (83).  
This was further investigated by carrying out a functional analysis by Seahorse 
extracellular flux analyzer, which was conducted with B cell populations as surrogates 
for ASCs since the paucity of such cells precludes their direct analysis for OCR or 
ECAR, which measures oxidative phosphorylation and glycolysis respectively. It is worth 
noting here, that upon stimulation, B cells similar to T cells increase glycolysis, which is 
relatively inefficient for generating energy but provides building blocks needed for cell 
division and effector function. However, unlike T cells B cells also increase energy 
production though OXPHOS. Our experiment showed that aged B cells without further 
activation appear to be metabolically more active. However, upon stimulation, aged B 
cells showed increased glycolysis, and this difference over resting B cells was 
comparable to those observed in young B cells. OCR, in contrast, only increased in 
young but not old B cells after mitogen-mediated stimulation, demonstrating severe 
mitochondrial defects, which only became obvious once cells had to increase energy 
production to allow for cell proliferation and effector function. OXPHOS can be fueled by 
numerous substrates including carbohydrates, amino acids and lipids, which generate 
NADH and FADH2 upon degradation in the TCA cycle. In turn, NADH and FADH2 are 
essential for the conversion of ADP to ATP, the energy currency of life, in the energy 
transport chain, which according to the array data was significantly altered upon aging.  
Previous studies demonstrated that the immunoinhibitor PD-1 is more highly expressed 
on aged CD4+ T cells (84). In the same token, we found that PD-1 expression increases 
on aged naïve B cells and on ASCs. PD-1 is typically viewed as an exhaustion marker 
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on T cells where it blocks activation of the AKT/mTOR pathway by T cell receptor and 
costimulator ligation (85) and thereby reduces the cells’ ability to use glycolysis for 
energy production (69). Previous data reported that PD-1 is expressed on B cells, where 
it was shown to inhibit B cell receptor signaling through the recruitment of the tyrosine 
phosphate SHP-2 (86). It is unknown if PD-1 affects glycolysis in B cells and thereby 
adds additional stress upon immunosenescence when energy production through 
OXPHOS becomes impaired. 
In summary, the goal of this study was to investigate the effect of immunosenescence on 
ASCs – specifically study immunoregulator expression and elucidate if aged ASCs were 
metabolically different from young ASCs. I achieved this with this study showing that 
bone marrow-derived ASCs, which are generated throughout a lifespan of an individual 
show substantial differences in their gene expression profile in aged as compared to 
young mice, which may explain their deteriorating functions. I also showed the increased 
expression of PD-1 on aged ASCs and its correlation with high levels of cellular ROS. 
This is a link that needs to be studied further.  
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Materials and methods: 
Mice: Mice were obtained from Charles River labs and housed in the Wistar Institute’s 
animal facility. Young mice were 6-8 weeks of age, and aged mice were >17 months of 
age. All procedures followed approved protocols. 
Sample collection: Mice were euthanized by CO2 asphyxiation, and samples were 
collected. Bone marrow samples were isolated from the bones of the hind legs of each 
mouse. Cells within the marrow were flushed out using a 27 ½ G syringe, and 
resuspended in prewarmed L-15 media (Life technologies, CA).  Whole spleens and 
PBMCs were also -collected. Spleen samples were ground up in L-15 media, and filtered 
through BD Falcon cell strainers. Cells from both samples were then counted using a 
haemocytometer, and resuspended in DMEM (Life technologies, CA) media containing 
10% Fetal Bovine Serum, Antibiotics (Pennicillin and Streptomycin).  
B cell analysis by flow cytometry: The following fluorochrome conjugated antibodies 
were used. CD3-Pacific Blue, CD14-Pacific Blue, AmCyan Aqua Blue Live/Dead stain, 
CD19, B220, IgD, PD-1, CD138 and  CellRox) Green mitochondrial dye.  
For assays with mitochondrial dyes, cells were stained with mitochondrial dyes, diluted 
in media for 45 minutes at 37o Celsius. Samples were then washed with PBS and then 
stained with fluorochorome-conjugated antibodies. For assays without the mitochondrial 
dyes, the previous step was omitted. Samples were stained for 30 minutes at room 
temperature, washed with PBS and then resuspended in 100μl of CytoFix/CytoPerm (BD 
Pharmingen) for 30 minutes. Samples were then washed with 100uL of BD PermWash, 
and stained for intracellular markers with fluorocohrome conjugated antibodies, diluted in 
PermWash for 30 minutes at 4o Celsius.  All antibodies were obtained from BD 
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Biosciences (San Jose, CA) unless otherwise specified. The stained samples were 
analyzed in a LSRII flow cytometer (BD Biosciences, San Jose, CA). 
Microarrays: Bone marrow resident cells were isolated as described above, and stained 
for extracellular markers. Cells were then sorted on a FACS ARIA fluorescent cell sorter 
for ASCs. Total RNA and small RNA were isolated from sorted ASCs using the modified 
protocol of Ambion RNAqueous -Micro kit (cat #AM1931) to recover the small RNAs.  
The amount of total RNA was measured by Nanodrop and run on Agilent RNA 6000 pico 
kit (cat # 5067-1513).  Total RNA at 10ng was amplified with NuGEN Ovation PicoSL 
WTA system (cat # 3310-48) to generate amplified cDNA, which was then labeled with 
Biotin (NuGEN Encore BiotinIL Module, cat # 4210-48). 
Biotin labeled cDNA at 750ng obtained from ASCs of young and aged mice was 
hybridized to Illumina MouseWG-6 v2 whole genome BeadChips.  All arrays were 
processed in the Wistar Institute Genomics Facility. The data was submitted to GEO 
database (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE72224.  
Data Processing and Analysis: Arrays were quantile normalized and the data filtered 
to remove non-informative probes that were expressed at background levels in the 
majority of the samples or had a maximum fold change below 1.2 between any two 
samples.  A total of 25,988 probes were retained for further analysis.  Replicates 
available for 2 samples were averaged prior to statistical analysis.  A t-test with a p-value 
cutoff of 0.05 was used to identify differentially expressed genes between the aged and 
young mice. All preprocessing and microarray data analysis were conducted in MATLAB 
8.0.0.783. 
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Probes with a p-value < 0.01 (unless otherwise noted) and a minimum fold change of 1.4 
were selected for functional analysis. Ingenuity Pathway Analysis (IPA) and DAVID were 
used to identify enriched pathways and biological functions at a p-value cutoff of 0.05 
after multiple-test correction using the Benjamini procedure.  
Magnetic Separation: Magnetic separation of naïve B cells was carried out using the 
pan B cell isolation kit from Miltenyi Biotec (CA) as specified in their protocol. Cells were 
resuspended at a concentration of 107 cells per ml in the separation buffer. Amounts of 
magnetic separation cocktail containing biotinylated antibodies and Streptavidin 
conjugated magnetic beads were calculated per manufacturer’s instructions and added 
to the cells, and set aside for 10 minutes. The magnetic separation cocktail contained 
antibodies for T cells, macrophages, and non-B cells. The cells were then sorted using 
the magnet and resuspended in DMEM media containing 10% Fetal Bovine Serum, and 
antibiotics. These cells were used for Seahorse TM Extracellular Flux assays.  
B cells stimulation: B cells were stimulated with a mitogen cocktail consisting of S. 
Aureus capsid, PokeWeed Mitogen extract, a CpG oligonucleotide (ODN 2006) and 
murine-IL-4 (Prepro Biotech) for 24 hours for flux assays. Concentrations of mitogens 
were determined experimentally.  
Extracellular Flux assays: Cells were analyzed according to manufacturer’s 
instructions for the SeahorseTM analyzer, with the Mitochondrial Stress test kit (Seahorse 
Biosciences, MA). Cells were seeded at a concentration of 1 million cells per well of a 24 
well plate of the SeahorseTM analyzer.  
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Significance:  
There is an imperative need for better vaccines for the aging population especially better 
vaccines to influenza viruses. In the 2013-14 influenza season, the vaccine effectiveness 
was lowest among persons > 65 years, at just 39%. This was reflected by almost half the 
estimated hospitalizations (~188,795) in the year occurring within this age group (87). 
According to the CDC, in many years more than 90% of influenza deaths occur in this 
population, reiterating the need for a better vaccine (88).  
Creating better vaccines for the aged requires a detailed understanding of 
immunosenescence, with a focus on defects in B cells and ASCs – the source for 
neutralizing antibodies. The findings in this thesis help understand this phenomenon, 
and aim to serve as a stepping stone for future studies that hopefully will eventually 
result in in better vaccines for the aged.  
Conclusions and future directions:  
In accordance with the overarching hypothesis, this thesis has shown significant 
differences in expression of immunoregulators on ASCs and their precursors, 
differences in metabolism and has identified potential links between these two factors.  
In chapter 2, I show that aged ASCs in humans expressed significantly lower levels of 
CD27 and CD38 on their surface, two markers that are used for identifying human ASCs 
by techniques like flow cytometry. This finding has considerable implications in 
immunosenescence – primarily that we need another marker to measure ASCs in aged 
humans, such as an intracellular stain for immunoglobulins.   Secondly, both CD27 and 
CD38 also play a role in signaling, and the decline in expression of these two surface 
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markers on ASCs, could indicate a potential loss of signaling, another possible reason 
for the decreased immune responses seen in the aged.  
In chapter 3, I show that BTLA expression on B cells in humans declined significantly 
upon aging. This finding has several implications. Firstly, this is the first report to indicate 
a role for BTLA on B cell functions and it's the first time that age-related differences in its 
expression levels were observed. BTLA expression and its signaling pathway have been 
studied in T cells, where blocking BTLA with the glycoprotein D of the Herpes Simplex 
Virus (HSV gD) increases T cell responses to vaccines (58), but its role in B cells is 
largely unknown. Secondly, the relationship between BTLA expression on mature B cells 
prior to vaccination, and increases in IgG titers along with concurrent decreases in IgM 
titers, indicates a potential role for BTLA in shifting the immune response from IgM to 
IgG or from plasma cell development towards class switching. This could be of vital 
importance in vaccine design. Finally, the link between high levels of BTLA on switched 
memory B cells to better VNA responses to the influenza A strains, in the following year 
is fascinating. This suggests a different role for BTLA – as a promoter of ASCs and 
memory B cells, rather than an inhibitor, as it is currently thought of. This is a hypothesis 
that needs to be studied further.  
Decreased immunoglobulin class switching, and lesser germinal center formation have 
been previously described in the aged, and have been implicated in the lower quality of 
humoral responses. The above-mentioned findings of this thesis corroborate this, and 
offer new insights into these defects. Low expression of CD27 and CD38 on circulating 
ASCs of the aged might reflect the decreased germinal center formation observed in this 
population. In addition, the low expression of these molecules could also have an effect 
on signals received by these ASCs. i.e., both CD27 and CD38 have been shown the 
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ability to transmit signals. CD27 has been observed to affect survival and proliferation 
signals, via the NF-KB pathway, while CD38 signaling plays a role in cell adhesion and 
lymphocyte trafficking and modulates intracellular NAD+ levels and sirtuins. The findings 
from chapter 3 also corroborate this. Low BTLA expression on aged mature B cells was 
also linked to decreased class switching in the aged. Thus loss of these markers upon 
aging could affect B cell fate decisions, and push them towards a non-GC path.  
There are some caveats in the human studies mentioned above that need to be 
readdressed. All human studies are performed with certain limitations. Our studies were 
limited to blood, which only allows assessing cells that are circulating. Long-lived ASCs 
reside primarily in the bone marrow and spleen, and since these specimens cannot be 
acquired readily in humans especially in highly vulnerable aged individuals, circulating 
ASCs were used although they are unlikely to be representative of the whole cell 
population. Another limitation was cell numbers. Metabolic assays – like the ones using 
the SeahorseTM extracellular flux analyzer – require high cell numbers to generate 
accurate readouts, and the limited availability of PBMCs prevented the usage of these 
techniques in the human studies. In addition, we obtained human samples from our 
collaborator at Duke University. Metabolism changes very rapidly once cells are 
harvested. The time needed for shipment of the samples to my laboratory precluded 
accurate assessment of metabolic differences between young and aged human B cells. 
In the same token gene profiling of B cell subsets, which gives unprecedented 
information about differences between two cohorts, is sensitive to time delays between 
removing cells from their physiological environment, i.e., the blood of the human 
subjects, and isolation and preservation of messenger RNA. I circumvented these 
caveats by studying B cell immunosenescence in mice, as described in chapter 4.  
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In chapter 4, I show that ASCs in mice also expressed different levels of 
immunoregulators upon aging, and they were metabolically different compared to the 
young. Similar to their human counterparts, aged mice had lower levels of mature B cells 
and ASCs. However, the most interesting observations came from samples and 
techniques that couldn’t be replicated in humans. Micro-array analysis of bone marrow 
derived ASCs (which are generated throughout the lifespan of an animal) revealed 
significant differences in gene expression upon aging. These ASCs were from the 
primary reservoir of long-lived plasma cells, which are responsible for maintaining levels 
of neutralizing antibodies in the blood, and are thus vital in the success or failure of 
vaccinations. Metabolic assays – extracellular flux analysis with the SeahorseTM analyzer 
– showed the inability of aged B cells to respond to mitogen-mediated stimulation on par 
with younger B cells; specifically a need for increased energy production following 
stimulation could not be satisfied by an increase in oxidative phosphorylation but rather 
had to rely on increases in the less efficient glycolysis pathway upon aging. Furthermore, 
this study revealed another relationship between immunoregulator expression and 
metabolism. Specifically, the increased expression of PD-1 on aged naïve B cells and 
ASCs, and its correlation with high levels of cellular ROS.  PD-1 is known to affect many 
metabolic pathways> It blocks Akt/mTOR signaling and thereby reduces glycolysis. 
Combined with the observed defects in OXPHOS these results suggest that aged B cells 
are poorly suited to increase energy production when challenged. The observed 
correlation between PD-1 and cROS levels is very interesting; also additional studies are 
needed to trace the source of the ROS. Most ROS is produced by mitochondrial during 
OXPHOS but ROS can also be produced by oxidative processes within the ER or 
peroxisomes.  It should also be noted that ROS is involved in signaling including 
activation of Akt, which directly opposes PD-1 signaling (89). Furthermore mitochondrial 
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ROS has been described to play a role in B cells’ fate decisions (90).  
his finding also provides new insights into the defective metabolism of aged B cells. 
Specifically, the increased levels of PD-1 on aged B cells and their correlation with 
cellular ROS levels point towards an exhausted phenotype. This is a hypothesis that 
needs to be investigated further, but it is the author’s opinion that the combination of 
high expression of a well-studied exhaustion marker (PD-1) along with the reduced 
ability to meet energy demands (inability to increase OXPHOS upon stimulation) 
indicates exhaustion. 
Another observation is that while the aged B cells show decreased OXPHOS upon 
stimulation, they still express increased levels of cellular ROS. Since OXPHOS is one of 
the major contributors of cellular ROS, this appears to suggest that ROS clearance 
pathways might be defective in the aged. This is another hypothesis that needs to be 
investigated further. Another major caveat that needs to be addressed is the apparent 
lack of congruity between the mouse and human studies. BTLA appears to play a role in 
human B cell immunosenescence, but not in mice where I found expression levels to be 
comparable between aged and young B cells. PD-1 on the other hand was differentially 
expressed in an age-dependent manner in mice but not humans. While both 
immunoregulators may exhibit links to metabolism, as is thus far only known for PD-1, 
their signaling pathways are quite different. To address this caveat, we need to 
understand the differences between these two immune systems. Firstly, while the mouse 
immune system has been extensively studied, has played an enormous role in our 
understanding of immunology and is considered by most as an acceptable model for the 
human immune system, there are still considerable differences between the two species. 
Hence, it is possible that while both species have a link between immunoregulator 
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expression and metabolism, the specific nature of that link – the molecules involved for 
example – could be very different.  
In summary, this thesis addresses my hypothesis, that:  
a. Expression levels of immunoregulators on ASCs or their precursor populations 
change upon aging.  
b. Aged ASCs or their precursors are metabolically different from their younger 
counterparts, and  
c. These two factors are linked.  
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